Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1

  1. Mathew Clement  Is a corresponding author
  2. Kristin Ladell
  3. Kelly L Miners
  4. Morgan Marsden
  5. Lucy Chapman
  6. Anna Cardus Figueras
  7. Jake Scott
  8. Robert Andrews
  9. Simon Clare
  10. Valeriia V Kriukova
  11. Ksenia R Lupyr
  12. Olga V Britanova
  13. David R Withers
  14. Simon A Jones
  15. Dmitriy M Chudakov
  16. David A Price
  17. Ian R Humphreys
  1. Division of Infection and Immunity, School of Medicine, Cardiff University, United Kingdom
  2. Systems Immunity Research Institute, School of Medicine, Cardiff University, United Kingdom
  3. Wellcome Sanger Institute, Wellcome Genome Campus, United Kingdom
  4. Center of Life Sciences, Skolkovo Institute of Science and Technology, Russian Federation
  5. Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Russian Federation
  6. Institute of Clinical Molecular Biology, Christian-Albrecht-University of Kiel, Germany
  7. Institute of Translational Medicine, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Russian Federation
  8. Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom
  9. Abu Dhabi Stem Cell Center, United Arab Emirates

Abstract

Inhibitory CD4+ T cells have been linked with suboptimal immune responses against cancer and pathogen chronicity. However, the mechanisms that underpin the development of these regulatory cells, especially in the context of ongoing antigen exposure, have remained obscure. To address this knowledge gap, we undertook a comprehensive functional, phenotypic, and transcriptomic analysis of interleukin (IL)-10-producing CD4+ T cells induced by chronic infection with murine cytomegalovirus (MCMV). We identified these cells as clonally expanded and highly differentiated TH1-like cells that developed in a T-bet-dependent manner and coexpressed arginase-1 (Arg1), which promotes the catalytic breakdown of L-arginine. Mice lacking Arg1-expressing CD4+ T cells exhibited more robust antiviral immunity and were better able to control MCMV. Conditional deletion of T-bet in the CD4+ lineage suppressed the development of these inhibitory cells and also enhanced immune control of MCMV. Collectively, these data elucidated the ontogeny of IL-10-producing CD4+ T cells and revealed a previously unappreciated mechanism of immune regulation, whereby viral persistence was facilitated by the site-specific delivery of Arg1.

Editor's evaluation

This study analyzes the development and functional relevance of IL-10-producing regulatory T cells in a mouse model of cytomegalovirus infection. The results indicate that IL-10-producing CD4+ T cells express genes associated with chronically activated TH1-like cells, undergo clonal expansion, and inhibit antiviral T cell responses via the secretion of arginase, an enzyme that breaks down an amino acid required for T cell activation and proliferation. These findings reveal a novel and important immunoregulatory mechanism that facilitates viral persistence.

https://doi.org/10.7554/eLife.79165.sa0

Introduction

Immune dysregulation occurs during many persistent viral infections. High levels of ongoing viral replication, which characterize human immunodeficiency virus (HIV), hepatitis B virus (HBV), and, in mice, lymphocytic choriomeningitis virus (LCMV), typically lead to T cell exhaustion, defined by impaired effector functions, the expression of inhibitory cytokines and receptors (Wherry, 2011), and substantial alterations in cellular gene expression (Doering et al., 2012). Moreover, inducible and naturally occurring FoxP3+ regulatory T cells accumulate during many chronic viral infections, presumably to limit excessive immune activation (Veiga-Parga et al., 2013), and T helper (TH)1-like cells that express the immunosuppressive cytokine interleukin (IL)-10 can be induced by LCMV (Parish et al., 2014), HIV (Graziosi et al., 1994), and human/murine cytomegalovirus (HCMV/MCMV) (Clement et al., 2016; Jones et al., 2010; Mason et al., 2013). Evidence from parasitic infections suggests that IL-10-producing TH1-like cells protect against immune pathology, akin to classical FoxP3+ regulatory T cells (Anderson et al., 2007; Jankovic et al., 2007). However, experimental deletion of IL-10 production in T cells has been shown to promote the clearance of LCMV without any obvious collateral effects (Clement et al., 2016; Parish et al., 2014; Richter et al., 2013), suggesting a potential therapeutic role for similar manipulations in humans, albeit with the possibility of an attendant risk to the development of CD8+ T cell memory (Laidlaw et al., 2015).

The mechanisms that induce IL-10 expression in T cells require further clarification, despite proposed roles for costimulatory receptors, cytokines, transcription factors, and signals delivered via the T cell receptor (TCR) (Saraiva and O’Garra, 2010). For example, chronic antigen exposure and the transcription factor Blimp-1 appear to be important for the development of IL-10-producing CD4+ T cells in mice infected with LCMV (Parish et al., 2014), and the inhibitory receptor TIGIT is known to act upstream of IL-10 (Schorer et al., 2020). However, it is clear that viral persistence can be facilitated by IL-10, exemplified in the context of MCMV infection by ongoing replication in the salivary glands (SGs) (Humphreys et al., 2007; Mandaric et al., 2012).

Interferon (IFN)γ-expressing CD4+ T cells have been shown to limit viral replication in the SGs of mice infected with MCMV (Jonjić et al., 1989; Lucin et al., 1992; Walton et al., 2011). Nonetheless, CD4+ T cells also represent an important source of IL-10 (Clement et al., 2016; Humphreys et al., 2007), the production of which is promoted by IL-27 during acute infection with MCMV. In contrast, less is known about the mucosal IL-10-producing CD4+ T cells that appear during chronic infection with MCMV, which are phenotypically distinct from type 1 regulatory T (Tr1) cells, specifically lacking concurrent expression of CD49d and LAG-3, and develop independently of IL-27 (Clement et al., 2016). These cells express high levels of various transcription factors, such as c-Maf and T-bet (Clement et al., 2016), and often coexpress other molecules with putative inhibitory functions, such as PD-1, TIM-3, and IL-21 (Apetoh et al., 2010; Awasthi et al., 2007; Chihara et al., 2018; Pot et al., 2009; Zhu et al., 2015). However, the functional relevance of these characteristics has remained obscure, along with the ontogeny of IL-10-producing CD4+ T cells during chronic infection with MCMV.

To address these issues, we performed a comprehensive functional, phenotypic, and transcriptomic analysis of IL-10-producing CD4+ T cells isolated from the SGs of mice infected with MCMV. Our data revealed that these cells were clonally expanded and highly differentiated TH1-like cells with gene expression signatures that indicated a key developmental role for T-bet. In addition, we identified an inhibitory effect attributable to arginase-1 (Arg1), which was upregulated among IL-10-producing CD4+ T cells during viral chronicity and facilitated the site-specific persistence of MCMV.

Results

IL-10-producing CD4+ T cells display a TH1-like profile

To better understand the development and functionality of inhibitory CD4+ T cells that develop during viral chronicity, we infected MCMV IL-10 reporter (10BiT) mice with MCMV. These mice express Thy1.1 under the Il10 promoter (Maynard et al., 2007). Unlike mucosal sites in the respiratory tract (Zhang et al., 2019), ongoing viral replication in this model occurs primarily in the SGs, facilitated by the induction of CD4+ T cells that produce IL-10 (Humphreys et al., 2007), which peak on day 14 post-infection (p.i.) (Clement et al., 2016). At this time point, we found that approximately 10–30% of CD4+ T cells in the SGs were Thy1.1+, of which ~95% displayed an effector memory phenotype (CD44hi CD62Llo) (Figure 1—figure supplement 1A). IL-10-producing CD4+ T cells were also induced by polyclonal stimulation and universally expressed Thy1.1 (Figure 1—figure supplement 1B).

We then compared the transcriptional profiles of endogenously generated IL-10+ and IL-10 CD4+ T cells, isolated via fluorescence-activated cell sorting (FACS) as Thy1.1+ (IL-10+) and Thy1.1 (IL-10) CD44hi CD62Llo CD4+ T cells (Figure 1—figure supplement 1A). Principal component analysis (PCA) of the RNA-seq data revealed that Thy1.1+ CD4+ T cells were transcriptionally distinct from Thy1.1 CD4+ T cells (Figure 1—figure supplement 1C). As expected, Il10 was highly upregulated in Thy1.1+ CD4+ T cells (Figure 1A), and chromatin was more open in the Il10 promoter region compared with Thy1.1 CD4+ T cells (Figure 1B). Genes associated with localization and cell migration (Ccl7, Cxcl2, Cxcl12, Ccl5, Cxcl14, Ccl28, Ccl12, Ccr1, and Ccr5), cell signaling (Ceacam1, Havcr2, Tigit, Lag3, Cd40, Cd36, and Itgb4), regulation of cellular processes (Prdm1, Gata2, Yes1, Card10, and Il33), and metabolism (Elovl7, Galnt3, Car13, Aldh1l1, and Ildrl), including glycolysis and the tricarboxylic acid cycle (Fbp2 and Sdhc), oxidative phosphorylation (Osgin1), and the mitochondrial respiratory chain (Mt-Nd1, Ndufs6, Ndufb8, Uqcrfs1, and Uqcr11), were also upregulated in Thy1.1+ CD4+ T cells, alongside genes associated with activation (Fgl2, Cxcr2, and Nfil3) and antiviral effector functions (Gzmb, Prf1, Gzmk, and Lyz2) (Figure 1A, C, D and Figure 1—figure supplement 1D). These latter gene profiles suggested the potential for cytolytic activity, but we found no evidence of a concomitant increase in the expression levels of granzyme B protein among Thy1.1+ CD4+ T cells (data not shown), which also lacked gene signatures classically associated with cytotoxic CD4+ T cells, such as the upregulation of Klrc1 and Crtam (https://doi.org/10.5281/zenodo.7243956).

Figure 1 with 1 supplement see all
Interleukin (IL)-10-producing CD4+ T cells display a TH1-like profile.

10BiT mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). Leukocytes were isolated from the salivary glands (SGs) on day 14 p.i. and sorted as CD4+ CD44+ CD62L CD90/90.1+ (Thy1.1+) or CD90/90.1 (Thy1.1) populations via fluorescence-activated cell sorting (FACS). (A) Volcano plot highlighting differentially upregulated genes in Thy1.1+ CD4+ T cells (red) versus Thy1.1 CD4+ T cells (blue). (B) ATAC-seq profiles showing accessible chromatin regions in the Il10 gene for Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). Data are shown as normalized values accounting for the total number of reads per lane. The black box indicates a major difference in chromatin accessibility. Black arrows indicate binding motifs for Tbx21. (C) Gene ontology analysis of data from (A) indicating the top six modules that were upregulated (red) or downregulated (blue) in Thy1.1+ CD4+ T cells. (D) Heatmap comparing data from (A) (left column) with published data from T-bet+ versus T-bet-knockout CD4+ T cells (middle column, GSE38808) and TH1 versus naive CD4+ T cells (right column, E-MTAB-2582). Displayed genes were selected according to relevant pathways identified via gene ontology analysis and tabulated against respective functions (all p < 0.05). (E) Venn diagram showing the overlap between genes enriched in Thy1.1+ CD4+ T cells (A, D) and genes enriched in TH1-like CD4+ T cells (E-MTAB-2582). Data in (A–E) are shown as pooled analyses from a minimum of n = 5 mice per group representing three independent experiments. (F) Representative histograms (top) and summary bar graphs (bottom) showing the expression of IL-7R and TCF1/7 among Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). The fluorescence-minus-one control is shown in sky blue (top). Bottom: data are shown as mean ± standard error of the mean (SEM; n = 10 mice per group representing two independent experiments). ****p < 0.0001 (Mann–Whitney U test). (G) Representative flow cytometry plots showing the expression of CD39 and TIM-3 among Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). Data are shown as pooled analyses from a minimum of n = 10 mice per group representing two independent experiments.

Figure 1—source data 1

Interleukin (IL)-10-producing CD4+ T cells display a TH1-like profile.

Source data Figure 1C: gene ontology analysis indicating the top six modules that were upregulated (red) or downregulated (blue) in Thy1.1+ CD4+ T cells isolated from the salivary glands (SGs) on day 14 p.i. (10BiT mice). Source data Figure 1F: percent expression of IL-7R and TCF1/7 among Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells isolated from the SGs on day 14 p.i. (10BiT mice).

https://cdn.elifesciences.org/articles/79165/elife-79165-fig1-data1-v1.xlsx

Thy1.1+ CD4+ T cells are known to express the TH1-associated chemokine receptors CXCR3 and CCR5 (Clement et al., 2016). We found that MCMV-induced Thy1.1+ CD4+ T cells shared many transcripts with CD4+ TH1 cells generated in vitro (Stubbington et al., 2015; Figure 1E), encompassing genes associated with numerous cellular and immunological processes (https://doi.org/10.5281/zenodo.7447477), and further expressed IFNγ in response to polyclonal stimulation at a population frequency of ~25% (Figure 1—figure supplement 1E). These data suggested that Thy1.1+ CD4+ T cells were commonly derived from antigen-specific TH1 cells, especially given that IFNγ detection via flow cytometry likely underestimates the composite frequency of CD4+ T cells that specifically recognize MCMV (Jeitziner et al., 2013). However, genes associated with the induction of IFNγ, including Il18r1 and il18rap, were actually downregulated in Thy1.1+ CD4+ T cells (Figure 1A, C, D), and in two of three replicates, a similar pattern was observed for Ifng (https://doi.org/10.5281/zenodo.7243956). Comparable findings were reported previously in functional studies of IFNγ expression at the protein level among IL-10-producing CD4+ T cells specific for HCMV or MCMV (Clement et al., 2016; Mason et al., 2013).

Other genes that were downregulated in Thy1.1+ CD4+ T cells included Il7 and Tcf1/7 (Figure 1A, D), which extended to the protein level (Figure 1F). The relative underexpression of these cell survival-associated factors coincided temporally with the rapid contraction of virus-specific IL-10-producing CD4+ T cells that typically occurs during the early stages of viral chronicity (Clement et al., 2016). In contrast, Thy1.1+ and Thy1.1 CD4+ T cells expressed similar levels of transcripts encoding DR5 (https://doi.org/10.5281/zenodo.7243956), which engages natural killer (NK) cell-expressed TRAIL and induces CD4+ T cell death in the SGs (Schuster et al., 2014).

IL-10 production among CD4+ T cells has been associated with the expression of inhibitory molecules and markers of exhaustion (Saraiva and O’Garra, 2010). Counterintuitively, we found that MCMV-induced Thy1.1+ CD4+ T cells downregulated the exhaustion-associated transcription factor Tox1 but nonetheless expressed a module of inhibitory genes, including Lag3, Fgl2, Havcr2, and Entpd1 (Figure 1D). These inhibitory molecules were also expressed at the protein level, alongside PD-1 (Figure 1G and Figure 1—figure supplement 1F). In addition, differential bystander activation seemed unlikely, because Thy1.1+ CD4+ T cells expressed LAG-3 and PD-1 more commonly than Thy1.1 CD4+ T cells after preselection based on the induction of IFNγ (Figure 1—figure supplement 1E).

Collectively, these data showed that IL-10-producing CD4+ T cells exhibited a highly differentiated TH1-like profile, characterized by the upregulation of various inhibitory molecules and the downmodulation of IFNγ expression lacking concordance with known signatures of exhaustion, during chronic infection with MCMV.

IL-10-producing CD4+ T cells exhibit prominent clonal structures

IL-10-producing CD4+ T cells recognize a broad range of viral antigens during chronic infection with MCMV (Clement et al., 2016). To characterize these interactions in more detail and evaluate the clonal relationship between IL-10+ (Thy1.1+) and IL-10 (Thy1.1) CD4+ T cells, we used a next-generation approach to sequence the corresponding TCRs.

The repertoires of Thy1.1+ CD4+ T cells were less diverse and incorporated more prominent clonal expansions compared with the repertoires of Thy1.1 CD4+ T cells (Figure 2A, B and Figure 2—figure supplement 1A). Several features also indicated that these expansions represented antigen-focused responses confined largely to Thy1.1+ CD4+ T cells (Figure 2C–G). First, the number of nucleotide variants that encoded each complementarity-determining region (CDR)3α and CDR3β amino acid sequence, an indicator of antigen-specific convergence (Logunova et al., 2020), was higher overall among Thy1.1+ CD4+ T cells versus Thy1.1 CD4+ T cells (Figure 2C). Second, there were some differences in Trbv gene use that distinguished Thy1.1+ CD4+ T cells from Thy1.1 CD4+ T cells, albeit with a general preference for Trbv3, Trbv5, and Trbv31 (Figure 2D). Third, clusters of homologous TCRβ variants, identified using the statistical model ALICE (Pogorelyy et al., 2019), were detected predominantly among Thy1.1+ CD4+ T cells (Figure 2E–G). Importantly, this latter model accounts for generation probabilities, reliably separating immunologically relevant and irrelevant public TCRs.

Figure 2 with 1 supplement see all
Interleukin (IL)-10-producing CD4+ T cells exhibit prominent clonal structures.

10BiT mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). Leukocytes were isolated from the salivary glands (SGs) on day 14 p.i. and sorted as CD4+ CD44+ CD62L CD90/90.1+ (Thy1.1+) or CD90/90.1 (Thy1.1) populations via fluorescence-activated cell sorting (FACS). (A) Clonality and (B) diversity metrics calculated for the T cell receptor (TCR)α (top) and TCRβ repertoires (bottom) derived from Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells. (C) TCR convergence measured as the average number of nucleotide sequences encoding amino acid-identical complementarity-determining region (CDR)3α (top) and CDR3β loops (bottom) across the 2000 most prevalent clonotypes. (A–C) p values were calculated using a paired t-test with Benjamini–Hochberg correction. ns, not significant. (D) Hierarchical clustering of Trbv gene use weighted by clonotype frequency. (E–G) Cluster analysis of the 500 most prevalent TCRβ clonotypes using the tcrgrapher pipeline. (E) The cumulative frequency of tcrgrapher hits per sample is shown in gray. The frequency of each cluster comprising at least two tcrgrapher hits was calculated for each sample and averaged across all six repertoires. The five most prevalent clusters are shown in color. (F) Amino acid logos for each of the five most prevalent clusters. (G) Visual representation of clusters comprising at least two tcrgrapher hits. Nodes represent unique amino acid sequences. Edges connect sequences with a single amino acid mismatch. Amino acid sequences present only in Thy1.1+ CD4+ T cells are shown in red, amino acid sequences present only in Thy1.1 CD4+ T cells are shown in blue, and amino acid sequences present in both Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells are shown in gray. Data are shown as pooled analyses from n = 4 mice per group representing three independent experiments (groups 1–3).

It should be noted that none of these differences were absolute. For example, the clusters of TCRβ variants identified among Thy1.1+ CD4+ T cells also occurred at lower cumulative frequencies among Thy1.1 CD4+ T cells (Figure 2E–G), and the TCRα and TCRβ repertoires overlapped considerably between Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells (Figure 2—figure supplement 1B). Moreover, there were no prominent differences in the physicochemical properties of amino acids in the central parts of the CDR3α and CDR3β loops, which generally differ among functionally discrete subsets of CD4+ T cells (Kasatskaya et al., 2020), to indicate an ontogenetic divergence between Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells (Figure 2—figure supplement 1C).

Collectively, these data revealed the presence of common molecular signatures that predominated among Thy1.1+ CD4+ T cells, consistent with the notion of an antigen-driven process of differentiation leading to the production of IL-10.

IL-10-producing CD4+ T cells are enriched for expression of Arg1

Our analysis of inhibitory gene expression revealed one particularly intriguing feature, namely that Thy1.1+ CD4+ T cells significantly upregulated Arg1 (Figure 1D). Arg1 promotes the catalytic breakdown of L-arginine (Munder, 2009) and has been shown to inhibit the proliferation of T cells (Czystowska-Kuzmicz et al., 2019; Rodriguez et al., 2004; Rodriguez et al., 2002). A previous study also reported that T cells could express Arg1 (Washburn et al., 2019), although the functional relevance of this observation has remained obscure.

To address this knowledge gap, we first confirmed expression at the protein level via Western blotting (Figure 3A) in experiments incorporating control mice lacking the ability to express Arg1 in the CD4+ lineage (Cd4Cre/+Arg1flox/flox). We then revealed the open chromatin structure around Arg1 in Thy1.1+ CD4+ T cells (Figure 3B) and further probed the expression of Arg1 versus Thy1.1 among CD4+ T cells via flow cytometry (Figure 3C). Our data showed that Arg1 was expressed by CD4+ T cells almost exclusively in the SGs (Figure 3A, C). Of note, Arg1 expression was also detected among CD8+ T cells but not among NK T cells via flow cytometry, although intracellular discrimination was subtle (Figure 3—figure supplement 1A). Depletion experiments nonetheless revealed that only CD4+ T cells contributed significantly to Arg1 protein concentrations in SG homogenates during chronic infection with MCMV (Figure 3—figure supplement 1B).

Figure 3 with 1 supplement see all
Interleukin (IL)-10-producing CD4+ T cells are enriched for expression of arginase-1 (Arg1).

(A) Expression of Arg1 among leukocytes isolated via magnetic separation from the salivary glands (SGs) and spleens of Cd4+/+Arg1flox/flox or Cd4Cre/+Arg1flox/flox mice on day 14 p.i. detected by Western blot. (B, C) 10BiT mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). (B) Leukocytes were isolated from the SGs on day 14 p.i. and sorted as CD4+ CD44+ CD62L CD90/90.1+ (Thy1.1+) or CD90/90.1 (Thy1.1) populations via fluorescence-activated cell sorting (FACS). ATAC-seq profiles show accessible chromatin regions in the Arg1 gene for Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). Data are shown as normalized values accounting for the total number of reads per lane. The black box indicates a major difference in chromatin accessibility. Black arrows indicate binding motifs for Tbx21. Data are shown as pooled analyses from a minimum of n = 5 mice per group representing three independent experiments. (C) Representative flow cytometry plots showing the expression of Arg1 versus Thy1.1 among CD4+ T cells isolated from the SGs and spleens on day 14 p.i. (A, C) Data are shown as pooled analyses from a minimum of n = 7 mice per group representing three independent experiments. (D) Representative flow cytometry plots showing the expression of Arg1 versus IL-10 among OT-II-specific CD4+ T cells generated in vitro in the absence or presence of IL-12 (3 ng/ml) ± OVA323–339 for 7 days and then stimulated with anti-CD3/CD28 for 4 hr. (E) Summary bar graph showing Arg1 protein concentrations in culture supernatants from (D) after stimulation with anti-CD3/CD28 for 48 hr. Up arrows indicate the higher concentration of OVA323–339 (0.5 μM), and down arrows indicate the lower concentration of OVA323–339 (0.01 μM). Data are shown as mean ± standard error of the mean (SEM).

Figure 3—source data 1

Interleukin (IL)-10-producing CD4+ T cells are enriched for expression of arginase-1 (Arg1).

Source data Figure 3A: expression of Arg1 among leukocytes isolated via magnetic separation from the salivary glands (SGs) and spleens of Cd4+/+Arg1flox/flox or Cd4Cre/+Arg1flox/flox mice on day 14 p.i. detected by Western blot. Original blots are shown for each antibody. Uncut blots are shown with black boxes to delineate the images used in Figure 3A.

https://cdn.elifesciences.org/articles/79165/elife-79165-fig3-data1-v1.zip
Figure 3—source data 2

Interleukin (IL)-10-producing CD4+ T cells are enriched for expression of arginase-1 (Arg1).

Source data Figure 3E: Arg1 protein concentrations in culture supernatants after stimulation of leukocytes with anti-CD3/CD28 for 48 hr measured via ELISA.

https://cdn.elifesciences.org/articles/79165/elife-79165-fig3-data2-v1.xlsx

IL-10-producing TH1 cells can be induced experimentally via high-dose antigen stimulation in the presence of IL-12 (Saraiva et al., 2009). Accordingly, we hypothesized that Arg1+ IL-10-producing CD4+ T cells might develop under similar conditions in vitro, given the corresponding TH1-like profile observed during chronic infection with MCMV. To test this notion, we stimulated ovalbumin (OVA)-specific transgenic CD4+ T cells from OT-II mice with high or low doses of the cognate peptide (OVA323–339) in the absence or presence of IL-12. Despite constitutively high expression levels of Arg1, only high-dose OVA323–339 in combination with IL-12 induced the development of CD4+ T cells that expressed Arg1 and IL-10, and importantly, all IL-10-producing CD4+ T cells coexpressed Arg1 (Figure 3D). Arg1 protein concentrations in culture supernatants also increased substantially after stimulation with high-dose OVA323–339 in the presence of IL-12 (Figure 3E).

Collectively, these data suggested that Arg1 expression was a hallmark of IL-10-producing CD4+ T cells, which developed almost exclusively in the SGs during chronic infection with MCMV.

CD4+ T cells promote viral persistence via expression of Arg1

To explore the biological relevance of our findings, we infected Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice with MCMV. Lineage-specific deletion of Arg1 did not impact the function or phenotype of CD4+ T cells in naive mice (Figure 3—figure supplement 1C, D). Higher numbers of IFNγ-expressing CD4+ T cells (Figure 4A) and higher frequencies of proliferating (Ki-67+) CD4+ T cells (Figure 4B) were nonetheless observed after viral antigen stimulation in the SGs of Cd4Cre/+Arg1flox/flox versus Cd4+/+Arg1flox/flox mice during the chronic phase of infection with MCMV. These data suggested that Arg1 inhibited the proliferation of CD4+ T cells in vivo, consistent with a previous in vitro study (Munder et al., 2006). Similarly, higher numbers of virus-specific CD8+ T cells, quantified using tetrameric antigen probes, were detected in the spleens of Cd4Cre/+Arg1flox/flox versus Cd4+/+Arg1flox/flox mice on day 30 p.i. (Figure 4C). In contrast, Arg1 deletion had no significant impact on the development of virus-specific IL-10-producing CD4+ T cells in the SGs (Figure 4D).

Figure 4 with 1 supplement see all
CD4+ T cells promote viral persistence via expression of arginase-1 (Arg1).

Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). (A) MCMV-specific CD4+ T cell responses in the salivary glands (SGs) on days 7 and 14 p.i. measured using flow cytometry to detect interferon (IFN)γ. Immunodominant peptides were pooled for stimulation. Data are shown as mean ± standard error of the mean (SEM; n = 4–6 mice per group representing three independent experiments). (B) Expression of Ki-67 among CD4+ T cells isolated from the SGs on day 14 p.i. measured via flow cytometry. Data are shown as mean ± SEM (n = 4–5 mice per group representing two independent experiments). (C) MCMV tetramer+ CD8+ T cells quantified in spleens on day 30 p.i. via flow cytometry. Data are shown as mean ± SEM (n = 4 mice per group representing two independent experiments). (D) MCMV-specific CD4+ T cell responses in the SGs on days 7 and 14 p.i. measured using flow cytometry to detect interleukin (IL)-10. Immunodominant peptides were pooled for stimulation. Data are shown as mean ± SEM (n = 8–10 mice per group representing two independent experiments). (A–D) *p < 0.05 (Mann–Whitney U test). (E) Viral genomes in saliva on days 7, 14, 21, and 28 p.i. measured via qPCR. Data are shown as mean ± SEM (n = 8 mice per group representing two independent experiments). *p < 0.05 (Mann–Whitney U test). (F) MCMV replication in SG homogenates on day 30 p.i. measured via plaque assay. Data are shown as individual points with median values (n = 6–7 mice per group representing two or three independent experiments). **p < 0.01 (Mann–Whitney U test).

Figure 4—source data 1

CD4+ T cells promote viral persistence via expression of arginase-1 (Arg1).

Source data Figure 4A: murine cytomegalovirus (MCMV)-specific CD4+ T cell responses in the salivary glands (SGs) on days 7 and 14 p.i. measured using flow cytometry to detect interferon (IFN)γ (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice). Source data Figure 4B: percent expression of Ki-67 among CD4+ T cells isolated from the SGs on day 14 p.i. measured via flow cytometry (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice). Source data Figure 4C: MCMV tetramer+ CD8+ T cells quantified in spleens on day 30 p.i. via flow cytometry (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice). Source data Figure 4D: MCMV-specific CD4+ T cell responses in the SGs on days 7 and 14 p.i. measured using flow cytometry to detect interleukin (IL)-10 (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice). Source data Figure 4E: viral genomes in saliva (DNA copies/μl) on days 7, 14, 21, and 28 p.i. measured via qPCR (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice). Source data Figure 4F: MCMV replication in SG homogenates (pfu/organ) on day 30 p.i. measured via plaque assay (Cd4+/+Arg1flox/flox and Cd4Cre/+Arg1flox/flox mice).

https://cdn.elifesciences.org/articles/79165/elife-79165-fig4-data1-v1.xlsx

IFNγ-expressing CD4+ T cells are known to restrict MCMV replication in the SGs (Walton et al., 2011). Accordingly, we found that viral shedding in the saliva (Figure 4E) and viral replication in the SGs (Figure 4F) were reduced in Cd4Cre/+Arg1flox/flox versus Cd4+/+Arg1flox/flox mice during the chronic phase of infection with MCMV. Importantly, no differences in viral replication were observed between Cd4Cre/+Arg1flox/flox and control mice at an earlier time point (day 14 p.i.) (Figure 4—figure supplement 1A), and deletion of Arg1 in myeloid cells, achieved using Lyz2Cre/+Arg1flox/flox mice, had no impact on viral shedding in the saliva or viral replication in the SGs (Figure 4—figure supplement 1B, C). Of note, there was also no evidence that Cd4Cre/+Arg1flox/flox mice were more susceptible to virus-induced autoimmunity, as indicated by anti-Sjögrens syndrome antigen (SSA) titers comparable to those observed in Cd4+/+Arg1flox/flox mice (Figure 4—figure supplement 1D).

Collectively, these data indicated that Arg1 expression by CD4+ T cells selectively inhibited the accumulation of virus-specific CD4+ and CD8+ T cells in the SGs, leading to suboptimal immune control of viral replication during chronic infection with MCMV.

IL-10-producing CD4+ T cells develop in a T-bet-dependent manner

In line with our previous work (Clement et al., 2016), we noted that Thy1.1+ CD4+ T cells expressed higher amounts of T-bet at the protein level than Thy1.1 CD4+ T cells (Figure 5A), and concordantly, we found that open chromatin was enriched in the Tbx21 region of Thy1.1+ CD4+ T cells versus Thy1.1 CD4+ T cells (Figure 5B). No such differences in expression intensity were observed for the related T-box transcription factor Eomesodermin (Eomes) (Figure 5—figure supplement 1A, B), which promotes the development of Tr1 cells (Roessner et al., 2021; Zhang et al., 2017). We also detected considerable overlap between the gene expression profiles of Thy1.1+ CD4+ T cells and T-bet-orchestrated CD4+ TH1 cells generated in vitro (Zhu et al., 2012; Figure 5C). Moreover, T-bet suppresses the expression of TCF1/7 and IL-7R (Dominguez et al., 2015; Oestreich et al., 2011), mimicking key phenotypic features of Thy1.1+ CD4+ T cells (Figure 1D, F). On the basis of these observations, we hypothesized that T-bet promoted the development of Arg1+ IL-10-producing CD4+ T cells during chronic infection with MCMV.

Figure 5 with 1 supplement see all
Interleukin (IL)-10-producing CD4+ T cells express T-bet and T-bet-inducible genes.

(A, B) 10BiT mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). (A) Leukocytes were isolated from the salivary glands (SGs) on day 14 p.i. Representative histograms (left) and summary bar graph (right) show the expression of T-bet among Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). Data are shown as mean ± standard error of the mean (SEM; n = 5–6 mice per group pooled from two independent experiments). MFI, median fluorescence intensity. **p < 0.01 (Mann–Whitney U test). (B) Leukocytes were isolated from the SGs on day 14 p.i. and sorted as CD4+ CD44+ CD62L CD90/90.1+ (Thy1.1+) or CD90/90.1 (Thy1.1) populations via fluorescence-activated cell sorting (FACS). ATAC-seq profiles show accessible chromatin regions in the Tbx21 gene for Thy1.1+ CD4+ T cells (red) and Thy1.1 CD4+ T cells (blue). Data are shown as normalized values accounting for the total number of reads per lane. The black boxes indicate major differences in chromatin accessibility. Data are shown as pooled analyses from a minimum of n = 5 mice per group representing three independent experiments. (C) Venn diagram showing the overlap between genes enriched in Thy1.1+ CD4+ T cells (A, D) and genes enriched in T-bet+ CD4+ T cells (GSE38808). (D) Cd4+/+Tbx21flox/flox (Cd4+/+) and Cd4CreERT2/+Tbx21flox/flox (Cd4Cre/+) mice were infected with 3 × 104 pfu of MCMV. Tamoxifen was administered (+Tam) or withheld (−Tam) from days 7 to 12 p.i. Leukocytes were isolated from the SGs on day 14 p.i. Representative flow cytometry plots show the expression of CD4 versus RFP (left) and CD44 versus T-bet for the gated populations (right). Data in the bar graph are shown as mean ± SEM (n = 4–5 mice per group representing four or five independent experiments). *p < 0.05, **p < 0.01 (Mann–Whitney U test).

Figure 5—source data 1

Interleukin (IL)-10-producing CD4+ T cells express T-bet and T-bet-inducible genes.

Source data Figure 5A: expression of T-bet (median fluorescence intensity, MFI) among Thy1.1+ CD4+ T cells and Thy1.1 CD4+ T cells isolated from the salivary glands (SGs) on day 14 p.i. measured via flow cytometry (10BiT mice). Source data Figure 5D: percent expression of CD4 versus T-bet among leukocytes isolated from the SGs on day 14 p.i. (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice).

https://cdn.elifesciences.org/articles/79165/elife-79165-fig5-data1-v1.xlsx

To test this notion, we crossed tamoxifen-inducible Cd4CreERT2/+ mice with Tbx21flox/flox mice (Intlekofer et al., 2008), allowing us to suppress T-bet expression at the onset of viral chronicity (day 7 p.i.). These mice were further crossed to incorporate a Rosa26flSTOPtdRFP allele (Luche et al., 2007), enabling the identification of cells in which Cre was expressed via the detection of tandem-dimer red fluorescent protein (tdRFP). Mice were then infected with MCMV. Tamoxifen was administered daily for 5 days from day 7 p.i. to deplete T-bet after initial antigen exposure in a CD4-dependent manner, an effect that clearly associated with the coincident expression of RFP (Figure 5D and Figure 5—figure supplement 1C).

CD4-specific T-bet depletion reduced the accumulation of virus-specific IL-10-producing CD4+ T cells (Figure 6A) and Arg1+ CD4+ T cells by day 14 p.i. (Figure 6B, C). However, it seemed unlikely that T-bet directly stimulated the expression of IL-10 and Arg1, because the corresponding binding motifs were not preferentially accessible in the Il10 and Arg1 regions (Figure 1B and Figure 3B). Instead, we observed a shift toward a less differentiated phenotype in Cd4CreERT2/+Tbx21flox/flox mice (Figure 6D–G), with decreased expression of CD44 (Figure 6D) and PD-1 (Figure 6E) and increased expression of CD62L (Figure 6F) and IL-7R (Figure 6G) in the absence of T-bet. In addition, T-bet depletion was associated with increased numbers of virus-specific IFNγ-expressing CD4+ T cells (Figure 6H) and enhanced control of viral replication in the SGs (Figure 6I), as well as reduced salivary shedding of MCMV (Figure 6J). In accordance with the observation that IL-10-producing CD4+ T cells occur transiently during the early stages of viral chronicity (Clement et al., 2016), we also found that CD4-specific T-bet depletion was no longer protective by day 28 p.i. (Figure 6J and Figure 5—figure supplement 1D).

Interleukin (IL)-10-producing CD4+ T cells develop in a T-bet-dependent manner.

(A–J) Cd4+/+Tbx21flox/flox (Cd4+/+) and Cd4CreERT2/+Tbx21flox/flox (Cd4Cre/+) mice were infected with 3 × 104 pfu of murine cytomegalovirus (MCMV). Tamoxifen was administered (+Tam) or withheld (−Tam) from days 7 to 12 p.i. Leukocytes were isolated from the salivary glands (SGs) on day 14 p.i. (A) MCMV-specific CD4+ T cell responses in the SGs measured using flow cytometry to detect IL-10. Immunodominant peptides were pooled for stimulation. Data are shown as mean ± standard error of the mean (SEM; n = 4–5 mice per group representing two independent experiments). **p < 0.01 (Mann–Whitney U test). Summary bar graph (B) and representative histograms (C) showing the expression of arginase-1 (Arg1) among CD4+ T cells measured via flow cytometry. Data are shown as mean ± SEM (n = 5 mice per group representing two independent experiments). ***p < 0.001 (Mann–Whitney U test). Summary bar graphs (left) and representative histograms (right) showing the expression of CD44 (D), PD-1 (E), CD62L (F), and IL-7R (G) among CD4+ T cells measured via flow cytometry. Data in (D–F) are shown as mean ± SEM (n = 5 mice per group representing two independent experiments). Data in (G) are shown as mean ± SEM (n = 3–4 mice per group representing two independent experiments). *p < 0.05, **p < 0.01 (Mann–Whitney U test). (H) MCMV-specific CD4+ T cell responses in the SGs measured using flow cytometry to detect interferon (IFN)γ. Immunodominant peptides were pooled for stimulation. Data are shown as mean ± SEM (n = 4–5 mice per group representing two independent experiments). *p < 0.05 (Mann–Whitney U test). (I) MCMV replication in SG homogenates on day 14 p.i. measured via plaque assay. Data are shown as individual points with median values (n = 10–14 mice per group pooled from three independent experiments). **p < 0.01 (Mann–Whitney U test). (J) Viral genomes in saliva on days 7, 14, 21, and 28 p.i. measured via qPCR. Data are shown as mean ± SEM (n = 5 mice per group representing two independent experiments). **p < 0.01 (Mann–Whitney U test). Data in (A–I) show all groups after the administration of tamoxifen.

Figure 6—source data 1

Interleukin (IL)-10-producing CD4+ T cells develop in a T-bet-dependent manner.

Source data Figure 6A: murine cytomegalovirus (MCMV)-specific CD4+ T cell responses in the salivary glands (SGs) on day 14 p.i. measured using flow cytometry to detect IL-10 (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice). Source data Figure 6B: percent expression of arginase-1 (Arg1) among CD4+ T cells isolated from the SGs on day 14 p.i measured via flow cytometry (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice). Source data Figure 4D–G: percent expression of CD44 (D), PD-1 (E), CD62L (F), and IL-7R (G) among CD4+ T cells isolated from SGs on day 14 p.i. measured via flow cytometry (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice). Source data Figure 6H: MCMV-specific CD4+ T cell responses in the SGs on day 14 p.i. measured using flow cytometry to detect interferon (IFN)γ (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice). Source data Figure 6I: MCMV replication in SG homogenates (pfu/organ) on day 14 p.i. measured via plaque assay (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice). Source data Figure 6J: viral genomes in saliva (DNA copies/μl) on days 14, 21, and 28 p.i. measured via qPCR (Cd4+/+Tbx21flox/flox and Cd4CreERT2/+Tbx21flox/flox mice).

https://cdn.elifesciences.org/articles/79165/elife-79165-fig6-data1-v1.xlsx

Collectively, these results suggested that T-bet exhibited dual functionality under conditions of recurrent antigen stimulation, concurrently driving the accumulation of virus-specific TH1 responses and promoting the development of Arg1+ IL-10-producing CD4+ T cells, which together shaped immune control of viral replication during the early stages of chronic infection with MCMV.

Discussion

In this study, we identified IL-10-producing CD4+ T cells as highly differentiated TH1-like cells, which occurred transiently at mucosal sites of viral persistence under the strict governance of T-bet. These cells also expressed the metabolic enzyme Arg1. Further investigation revealed that Arg1 expression was a critical immune regulatory function of CD4+ T cells, suppressing antiviral immunity and facilitating viral chronicity in the context of infection with MCMV.

Our finding that Arg1 was one of the putative immune regulatory genes expressed by IL-10-producing CD4+ T cells was initially counterintuitive, given the reported lack of Arg1 protein expression by human CD4+ T cells in vitro (Geiger et al., 2016). However, Arg1 expression by CD4+ and CD8+ T cells has been described in patients with sepsis (Washburn et al., 2019), indicating a potential role for generic infectious stimuli and/or an antigen-driven process mediated via the TCR. The latter possibility is consistent with our repertoire data, which revealed that prominent clonal expansions were associated with the production of IL-10. Importantly, we demonstrated that Arg1 was expressed at the protein level, both in secreted form and intracellularly. It should be noted that relatively weak intracellular signals were detected in flow cytometric analyses of C57BL/6 mice, akin to an earlier study of patients infected with HBV (Pallett et al., 2015). Western blotting experiments nonetheless clearly showed that CD4+ T cells expressed Arg1 in the SGs of mice chronically infected with MCMV. Our flow cytometry experiments also suggested that CD8+ T cells could express Arg1, albeit with the caveat of suboptimal visualization, but importantly, CD4+ T cells secreted far greater amounts of soluble Arg1, at least in the milieu of the SGs.

L-arginine deficiency results in cell cycle arrest via the downregulation of CD3ζ, a key component of the TCR (Rodriguez et al., 2002), and T cell proliferation is impaired in the absence of L-arginine (Rodriguez et al., 2007). In line with these observations, we found that improved control of viral replication in mice lacking Arg1+ CD4+ T cells was associated with increased numbers of MCMV-specific effector CD4+ T cells, which are known to limit viral replication in the SGs (Lucin et al., 1992; Walton et al., 2011). Accordingly, the acquisition of Arg1 expression by highly differentiated CD4+ T cells impinges on antiviral immunity, representing an inhibitory mechanism that operates alongside the production of IL-10 (Clement et al., 2016; Humphreys et al., 2007). It is also notable here that regulatory T cells may act similarly via the expression of Arg2 (Lowe et al., 2019).

IL-10 is regulated by a number of transcription factors, including those required for T cell differentiation, and is induced downstream of the TCR (Saraiva et al., 2020). Our discovery that T-bet promotes the development of IL-10-producing CD4+ T cells aligns with the concept that chronic antigen stimulation can trigger a negative feedback loop via these mechanisms, which concurrently drive activation and differentiation. It nonetheless remains less clear to what extent T-bet directly orchestrates the expression of other inhibitory molecules by CD4+ T cells. There was no notable increase in chromatin-accessible binding motifs for T-bet within either the Il10 or Arg1 genes in IL-10-producing CD4+ T cells. However, we did find that deletion of T-bet after acute infection limited the accumulation of highly differentiated CD4+ T cells, including those expressing Arg1 and IL-10. In line with this observation, which suggested a differentiation-linked process of functional remodeling driven by chronic antigen exposure, T-bet is known to promote the differentiation of CD8+ T cells (Dominguez et al., 2015; Omilusik et al., 2015) and inhibit the expression of TCF1/7 (Omilusik et al., 2015) and IL-7R (Intlekofer et al., 2007), both of which were downregulated among Arg1+ IL-10-producing CD4+ T cells induced by MCMV.

The relationship between mucosal IL-10-producing CD4+ T cells and classical Tr1 cells requires further clarification. In contrast to Tr1 cells (Gagliani et al., 2013), IL-10-producing CD4+ T cells in the SGs do not coexpress CD49b and LAG-3 (Clement et al., 2016), highlighting the diverse nature of regulatory CD4+ T cells defined by the secretion of IL-10 (Brockmann et al., 2018). However, these cells do express multiple inhibitory receptors, including LAG-3, alongside other markers that typically characterize Tr1 cells, such as CCR5 and granzyme K (Brockmann et al., 2018; Roessner et al., 2021; Thelen et al., 2023). In our model, Thy1.1+ CD4+ T cells also expressed Eomes, akin to clonally expanded T-bet-dependent Tr1 cells (Thelen et al., 2023). Accordingly, mucosal IL-10-producing CD4+ T cells may develop along similar lines to conventional Tr1 cells, which differentiate under the control of Eomes in conjunction with Blimp-1 (Roessner et al., 2021; Zhang et al., 2017).

The mechanisms that directly induce the expression of Il10 and Arg1 in CD4+ T cells remain obscure. Although IL-10-producing CD4+ T cells were characterized by prominent clonal expansions, repertoire analysis revealed no obvious determinative role for the TCR. However, the transcription factor c-Maf, which promotes the expression of IL-10 in multiple TH cell subsets (Gabryšová et al., 2018), is known to be upregulated in IL-10-producing CD4+ T cells during chronic infection with MCMV (Clement et al., 2016). We also demonstrated previously that ICOS signaling promotes the accumulation of IL-10-producing CD4+ T cells under the same conditions (Clement et al., 2016), and c-Maf acts downstream of ICOS (Bauquet et al., 2009; Nurieva et al., 2003). It therefore seems likely that an ICOS–c-Maf axis participates in the direct induction of Il10, although it is less clear how this applies to Arg1. Moreover, we found that Arg1+ IL-10-producing CD4+ T cells developed optimally in vitro in response to high-dose antigen stimulation in the presence of IL-12, suggesting determinative roles for ERK MAP kinase and the transcription factor STAT4 (Saraiva et al., 2009).

The evolutionary advantage of a mechanism that leads to the production of immune regulatory molecules and consequently facilitates viral persistence without impacting autoimmunity is difficult to explain. One possibility is that some of these molecules, potentially including Arg1, serve to maintain tissue health in the presence of ongoing inflammation. It would be informative in this context to evaluate how Arg1 delivery via CD4+ T cells impacts mucosal pathology over time at sites beyond the SGs. Alternatively, local immune suppression may somehow limit the emergence of more pathogenic viral strains under conditions of persistent replication, thereby protecting the host and the wider population. Irrespective of the precise explanation, it seems clear that viral persistence can be facilitated by this intrinsic regulatory mechanism, a phenomenon that could feasibly extend to pathogens other than MCMV.

In summary, we have demonstrated that T-bet activity during a chronic viral infection can impede antiviral immune control by driving the development of highly differentiated TH1-like cells that express genes encoding inhibitory molecules, including IL-10 and Arg1. Importantly, these Arg1+ IL-10-producing CD4+ T cells developed in vitro under conditions of extreme antigen stimulation, especially in the presence of IL-12, and the expression of Arg1, which was also secreted in vivo as a soluble immune regulatory protein, facilitated viral replication during the chronic phase of infection with MCMV. These observations are conceivably important not only from a biological perspective but also from a translational perspective, revealing a previously unappreciated mechanism through which CD4+ T cells can suppress potentially harmful immune responses via the regulation of L-arginine.

Materials and methods

Mice

10BiT reporter mice were originally derived by Padraic Fallon (Trinity College Dublin, Republic of Ireland). These mice express CD90/CD90.1 (Thy1.1) under the control of the Il10 promoter and retain endogenous expression of IL-10 (Maynard et al., 2007). Cd4+/+Tbx21flox/flox mice and Cd4CreERT2/+Tbx21flox/flox mice were generated by crossing Rosa26flSTOPtdRFP mice (Luche et al., 2007) with Tbx21flox/flox mice (Intlekofer et al., 2008). Arg1flox/flox mice (JAX stock #008817) and Lyz2Cre/+ mice (JAX stock #004871) were purchased from The Jackson Laboratory. These mice were bred to generate Lyz2+/+Arg1flox/flox mice and Lyz2Cre/+Arg1flox/flox mice. Arg1flox/flox mice were further bred with Cd4Cre/+ mice to generate Cd4+/+Arg1flox/flox mice and Cd4Cre/+Arg1flox/flox mice. C57BL/6 WT mice (JAX stock #000664) were purchased from Charles River or Envigo. OT-II mice (JAX stock #004194) were purchased from The Jackson Laboratory. Cd4Cre/+ mice (JAX stock #022071) were a kind gift from Sarah Dimeloe (University of Birmingham, UK).

Infections and treatments

Request a detailed protocol

MCMV was prepared via sorbital gradient purification as described previously (Stacey et al., 2014). Mice were infected with 3 × 104 pfu of MCMV intraperitoneally. Cd4+/+ and Cd4Cre/+ mice were injected intraperitoneally with tamoxifen (Sigma-Aldrich) as indicated for 5 days from day 7 p.i. at a daily dose of 75 mg/kg (20 mg/ml). In some experiments, mice were injected intraperitoneally with anti-CD4 (100 μg of clone GK1.5 and 100 μg of clone YTS191) and/or anti-CD8 (100 μg of clone YTS169.4 and 100 μg of clone YTS156.7.7) or an isotype control, rat IgG2b anti-keyhole limpet hemocyanin (400 μg of clone LTF-2), on days 6 and 8 p.i. (all from BioXell).

Next-generation sequencing

Request a detailed protocol

Leukocytes were isolated directly ex vivo from the SGs of 10BiT mice on day 14 p.i. (minimum n = 5 mice per group with three replicates). Pooled cells were labeled using a Zombie Aqua Fixable Viability Kit (BioLegend) and stained with anti-CD16/CD32 (Fc block, BioLegend) followed by anti-CD4–BV605 (clone RM4-5, BioLegend), anti-CD44–FITC (clone IM7, BioLegend), anti-CD62L–PE-Cy7 (clone MEL-14, BioLegend), and anti-CD90/90.1–PE (clone OX-7, BioLegend). Cells were sorted as CD4+ CD44+ CD62L CD90/90.1+ (Thy1.1+) or CD90/90.1 (Thy1.1) populations directly into Buffer RLT or Buffer RLT Plus (QIAGEN) using a modified FACS Aria II (BD Biosciences). Total RNA was extracted using an RNeasy Micro Kit or an RNeasy Mini Kit (QIAGEN), and RNA integrity scores were determined using an RNA 6000 Pico Kit (Agilent).

RNA-seq

Request a detailed protocol

Multiplexed mRNA libraries were obtained using a TruSeq RNA Library Prep Kit v2 (Illumina) and analyzed using a Bioanalyzer High Sensitivity DNA Chip (Agilent). Libraries were sequenced using a HiSeq 2500 System (Illumina). Paired-end reads (100 bp) were trimmed using Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and assessed for quality using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were mapped to the mouse GRCm38 reference genome using STAR (Dobin et al., 2013). Counts were assigned to transcripts using featureCounts (Liao et al., 2014) with the GRCm38.84 Ensembl gene build GTF (http://www.ensembl.org/info/data/ftp/index.html/). Differential gene expression analyses were performed using DESeq2 (Love et al., 2014). Genes were discarded from the analysis if differential expression failed to reach significance (adjusted p < 0.05 with Benjamini–Hochberg correction).

ATAC-seq

Request a detailed protocol

ATAC-seq was performed as described previously (Buenrostro et al., 2013) using a Nextera DNA Sample Preparation Kit (Illumina). DNA was isolated after library preparation using a MiniElute PCR Purification Kit (QIAGEN). Size selection was performed using a BluePippin System (Sage Science) with 2% Agarose Gel Cassettes (Sage Science). Libraries were sequenced using a HiSeq 4000 System (Illumina). Paired-end reads (100 bp) were trimmed using Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and assessed for quality using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were mapped to the mouse GRCm38 reference genome using BWA (Li and Durbin, 2009). Duplicate reads were removed using MarkDuplicates (http://broadinstitute.github.io/picard/). Peaks were called using MACS2 (Zhang et al., 2008) in BAMPE mode (adjusted p < 0.05 with Benjamini–Hochberg correction). Differential analysis of open regions was performed using DiffBind (http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf).

TCR-seq

Request a detailed protocol

Unique molecular identifier (UMI)-labeled 5′-RACE TCR cDNA libraries were synthesized using a Mouse TCR Profiling Kit (MiLaboratories). Indexed samples were pooled and sequenced using a MiSeq System (Illumina). Paired-end reads (150 bp) were extracted and clustered by UMI using MiGEC (Shugay et al., 2014). Sequences were discarded from the analysis if the read count was <4 per cDNA. Error correction was performed using MiGEC. Repertoires were extracted using MiXCR (Bolotin et al., 2015). The weighted average use of bulky, charged, and strongly interacting (aromatic and hydrophobic) amino acids positioned centrally in the CDR3α/β sequences and Trbv gene use (weighted by frequency) were calculated using VDJtools (Shugay et al., 2015). Diversity was calculated by downsampling the repertoires to an equal number of UMIs (n = 4300 for TCRα and n = 3900 for TCRβ) three separate times and plotting the mean Chao1 index, reflecting lower bound total diversity, and (1 − normalized Shannon–Wiener index), reflecting clonality. Visualization was achieved using PlotQuantileStats in VDJtools. The mean number of unique nucleotide sequences encoding the same amino acid sequence (convergence) was calculated for the 2000 most prevalent clonotypes in each sample using VDJtools. Overlap was calculated for the 2000 most prevalent clonotypes using F2 metrics to estimate sharing at the amino acid level among V gene-matched sequences in each sample. Cluster analysis was performed using the 500 most prevalent clonotypes in pooled samples (Thy1.1+ versus Thy1.1). These datasets were analyzed using tcrgrapher (https://github.com/KseniaMIPT/tcrgrapher), an R library based on ALICE (Pogorelyy et al., 2019). The real and expected numbers of neighbors were calculated for each clonotype with a maximum of n = 1 amino acid mismatch. Clonotypes with a significantly higher number of neighbors than expected on statistical grounds (adjusted p < 0.0001 with Benjamini–Hochberg correction) were identified as tcrgrapher hits. The expected number of neighbors was estimated via generation probabilities calculated for each clonotype using OLGA (Sethna et al., 2019), with the selection factor set at Q = 6.27 (Elhanati et al., 2018).

Bioinformatics

Request a detailed protocol

RNA-seq analysis was performed using DESeq2/1.32.0, dplyr/1.0.7, and GenomicRanges/1.44.0. Volcano plots were drawn using ggplot2/3.3.5 and ggrepel/0.9.1. TCR-seq analysis was performed using MiGEC/1.2.9, MiXCR/3.0.13, VDJtools/1.2.1, tidyverse/1.3.1, igraph/1.2.6, ggnetwork/0.5.10, msa/1.22.0, tcrgrapher/0.0.09000, stringdist/0.9.6.3, and ggseqlogo/0.1. Other software packages used across next-generation sequencing platforms included Nextflow (https://www.nextflow.io/) (Di Tommaso et al., 2017), trimgalore/0.6.4 (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), FastQC/0.11.8 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), multiqc/1.7 (https://multiqc.info/) (Ewels et al., 2016), STAR/2.7.3 (https://github.com/alexdobin/STAR) (Dobin et al., 2013), BWA/0.7.10 (http://bio-bwa.sourceforge.net/) (Li and Durbin, 2009), picard/2.20.2 (http://broadinstitute.github.io/picard/), samtools/1.9 (http://www.htslib.org/) (Danecek et al., 2021), bamtools/2.5.1 (https://github.com/pezmaster31/bamtools) (Barnett et al., 2011), featurecounts/2.0.0 (http://subread.sourceforge.net/) (Liao et al., 2014), and MACS2/2.1.2 (https://pypi.org/project/MACS2/) (Zhang et al., 2008). Venn diagrams were drawn using InteractiVenn (http://www.interactivenn.net) (Heberle et al., 2015). Heatmaps were drawn using Morpheus (https://software.broadinstitute.org/morpheus). ATACseq data were visualized using Integrative Genomics Viewer (Robinson et al., 2011). Gene ontology analysis was performed using GOTermFinder (https://go.princeton.edu/cgi-bin/GOTermFinder). ATAC-seq motif analysis was performed using The MEME Suite (https://meme-suite.org/meme/doc/cite.html?man_type=web) (Bailey et al., 2015). Tbx21 binding motifs were obtained using JASPAR2020 (Fornes et al., 2020).

Quantification of MCMV

Request a detailed protocol

Infectious virus was quantified in organs via plaque assay as described previously (Stack et al., 2015). 3T3 cells were purchased directly from the American Type Culture Collection. Mycoplasma infection was excluded prior to assay. Viral loads in oral lavage were quantified via qPCR (Clement et al., 2016; Kamimura and Lanier, 2014).

Western blotting

Request a detailed protocol

Leukocytes were isolated from SGs and spleens as described previously (Stacey et al., 2011). CD4+ T cells were purified via magnetic separation using a MagniSort Mouse CD4 Positive Selection Kit (Thermo Fisher Scientific). Cell lysates were generated from equal numbers of cells using NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) supplemented with 100 mM dithiothreitol (Sigma-Aldrich). Samples were loaded onto 4–12% NuPAGE Bis-Tris Gels (Thermo Fisher Scientific) after boiling and transferred to a PVDF membrane using an XCell II Blot Module (Thermo Fisher Scientific). Blots were probed with anti-arginase-1 (rabbit polyclonal, Thermo Fisher Scientific) and developed using anti-rabbit IgG–HRP (Bio-Rad). Band intensity was determined using a G:BOX Gel Imaging System (Syngene). Blots were then stripped using Restore PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific) and probed again with anti-actin (rabbit polyclonal, Abcam).

Flow cytometry

Request a detailed protocol

Leukocytes were isolated from SGs and spleens as described previously (Stacey et al., 2011). Cells were labeled using a Zombie Aqua Fixable Viability Kit (BioLegend) and stained with anti-CD16/CD32 (Fc block, BioLegend) followed by combinations of anti-CD4–APC-Cy7, anti-CD4–BV605, or anti-CD4–Pacific Blue (clone RM4-5, BioLegend), anti-CD8–BV605 (clone 53.6.7, BioLegend), anti-CD39–Alexa Fluor 647 (clone Duha59, BioLegend), anti-CD44–FITC (clone IM7, BioLegend), anti-CD62L–BV711 or anti-CD62L–PE-Cy7 (clone MEL-14, BioLegend), anti-CD90/90.1–APC, anti-CD90/90.1–BV605, or anti-CD90/90.1–PE (clone OX-7, BioLegend), anti-CD127–BV711 (clone A7R34, BioLegend), anti-CD223–PE (LAG-3) (clone C9B7W, BioLegend), anti-NK1.1–PE (clone PK136, BioLegend), anti-PD-1–BV421 (clone 29F.1A12, BioLegend), anti-TIGIT–APC (clone 1G9, BioLegend), and anti-TIM-3–BV711 or anti-TIM-3–PerCP-Cy5.5 (clone RMT3-23, BioLegend). Tetramer staining was performed as described previously (Clement et al., 2016). The following specificities were used in this study: H-2Db M45 residues 985–993 (HGIRNASFI), H-2Kb IE3 residues 416–423 (RALEYKNL), H-2Kb M38 residues 316–323 (SSPPMFRV), and H-2Kb m139 residues 419–426 (TVYGFCLL) (National Institutes of Health Tetramer Core Facility). Internal antigen expression was determined after fixation/permeabilization in BD Cytofix/Cytoperm Solution (BD Biosciences) or FoxP3/Transcription Factor Staining Buffer (eBioscience). Cells were stained with combinations of anti-arginase-1–APC (clone Met1-Lys322, Bio-Techne) or anti-arginase-1–PE-Cy7 (clone A1ex5, eBioscience), anti-Ki-67–Alexa Fluor 488 (clone 11F6, BioLegend), anti-T-bet–BV605 or anti-T-bet–Pacific Blue (clone 4B10, BioLegend), and anti-TCF1/7–Alexa Fluor 647 (clone C63D9, Cell Signaling Technology). Cells were acquired using an Attune NxT (Thermo Fisher Scientific) or an LSR Fortessa (BD Biosciences). All flow cytometry data were analyzed using FlowJo v10.5.3 or v10.8.1 (FlowJo LLC).

Quantification of anti-SSA

Request a detailed protocol

Plasma samples were obtained from cardiac punctures and assessed for anti-SSA/Ro 60 IgG levels via ELISA (Alpha Diagnostics).

In vitro induction of Arg1

Request a detailed protocol

Spleens were harvested from OT-II mice (n = 13) and digested for 30 min via the injection of collagenase-D (Thermo Fisher Scientific). Cells were isolated and purified via magnetic separation using a Pan Dendritic Cell Isolation Kit (Miltenyi Biotec) and a MagniSort Mouse CD4 Positive Selection Kit (Thermo Fisher Scientific). Cultures were established using 2 × 104 purified CD11c+ dendritic cells/ml and 1 × 105 purified CD4+ T cells/ml as described previously (Saraiva et al., 2009). Cells were cultured in the absence or presence of IL-12 (3 ng/ml, PeproTech) without or with the OVA peptide ISQAVHAAHAEINEAGR (residues 323–339, GenScript) at a concentration of 0.01 or 0.5 μM in RPMI medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, and 10% heat-inactivated fetal calf serum (all from Thermo Fisher Scientific). On day 7, cells were unexposed (medium control) or exposed to plate-bound anti-CD3 (2 μg/ml, clone 145-2C11, BioLegend) and anti-CD28 (2 μg/ml, clone 37.51, BioLegend). After 2 hr, the cultures were supplemented without or with brefeldin A (2 μg/ml, Sigma-Aldrich), and after a further 2 hr, cells were labeled using a Zombie Aqua Fixable Viability Kit (BioLegend) and stained with anti-CD16/CD32 (Fc block, BioLegend) followed by anti-CD4–Pacific Blue (clone RM4-5, BioLegend) and anti-CD8–BV605 (clone 53.6.7, BioLegend). Internal antigen expression was determined after fixation/permeabilization in BD Cytofix/Cytoperm Solution (BD Biosciences). Cells were stained with anti-arginase-1–PE-Cy7 (clone A1ex5, eBioscience), anti-IFNγ–FITC (clone XMG1.2, BioLegend), and anti-IL-10–APC (clone JES5-16E3, eBioscience). Cells were acquired using an Attune NxT (Thermo Fisher Scientific), and data were analyzed using FlowJo v10.5.3 (FlowJo LLC). Supernatants were harvested from cultures that lacked brefeldin A after a further 48 hr and analyzed for Arg1 protein expression via ELISA (Aviva Systems Biology).

Functional assays

Request a detailed protocol

Leukocytes from SGs and spleens were stimulated with peptides at a final concentration of 3 μg/ml for 2 hr at 37°C. The following peptides were used to stimulate CD4+ T cells: m09 residues 133–147 (GYLYIYPSAGNSFDL), M25 residues 409–423 (NHLYETPISATAMVI), m139 residues 560–574 (TRPYRYPRVCDASLS), and m142 residues 24–38 (RSRYLTAAAVTAVLQ). The cultures were then supplemented with brefeldin A (2 μg/ml, Sigma-Aldrich) and incubated for a further 4 hr at 37°C. After stimulation, cells were labeled using a Zombie Aqua Fixable Viability Kit (BioLegend) and stained with anti-CD16/CD32 (Fc block, BioLegend) followed by anti-CD4–APC-Cy7 or anti-CD4–BV605 (clone RM4-5, BioLegend). Internal antigen expression was determined after fixation/permeabilization in BD Cytofix/Cytoperm Solution (BD Biosciences). Cells were stained with combinations of anti-IFNγ–APC-Cy7, anti-IFNγ–FITC, or anti-IFNγ–Pacific Blue (clone XMG1.2, BioLegend), anti-IL-10–APC or anti-IL-10–FITC (clone JES5-16E3, eBioscience), and anti-T-bet–BV605 (clone 4B10, BioLegend). Cells were acquired using an Attune NxT (Thermo Fisher Scientific), and data were analyzed using FlowJo v10.5.3 (FlowJo LLC).

Statistics

Sample sizes for next-generation sequencing experiments were calculated using G*Power (https://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower.html), where a minimum of n = 5 pooled mice per group was used to detect a difference in means with 90% power and an α value set at 0.05 across a minimum of three replicates. All outliers were included in the final datasets. Comparisons between two groups were performed using the Mann–Whitney U test. Significance across all tests is reported as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Data availability

All data needed to evaluate the conclusions of this study are presented in the paper and/or the Supplementary Materials. RNA-seq data generated as part of this study have been deposited in ArrayExpress (E-ERAD-445). A fully annotated version of the RNA-seq dataset is freely available via Zenodo (https://doi.org/10.5281/zenodo.7243956). An annotated list of genes shared between the dataset presented here (E-ERAD-445) and the in vitro TH1 dataset (E-MTAB-2582) is also freely available via Zenodo (https://doi.org/10.5281/zenodo.7447477). TCR-seq data generated as part of this study have been deposited in the NCBI Sequence Read Archive (PRJNA860054). Processed repertoire datasets are freely available via Figshare (https://figshare.com/projects/Clement_InhibitoryCD4/143541).

The following data sets were generated
    1. Clement M
    2. Humphreys IR
    (2021) ArrayExpress
    ID E-ERAD-445. Characterization of IL-10-producing CD4+ T cells in a mucosal herpesvirus infection.
    1. Clement M
    (2023) NCBI Sequence Read Archive
    ID PRJNA860054. TCR-seq data generated as part of this study.
    1. Clement M
    (2022) Zenodo
    RNA-seq data comparing salivary gland IL-10-producing CD4+ T cells versus IL-10-nonproducing CD4+ T cells on day 14 after infection with MCMV.
    https://doi.org/10.5281/zenodo.7243956
    1. Clement M
    (2022) Zenodo
    Shared gene use between salivary gland IL-10-producing CD4+ T cells and TH1-like CD4+ T cells generated in vivo.
    https://doi.org/10.5281/zenodo.7447477
The following previously published data sets were used
    1. Stubbington M
    2. Mahata B
    3. Svensson V
    4. Deonarine A
    5. Nissen JK
    (2015) ArrayExpress
    ID E-MTAB-2582. An mRNA-sequencing atlas of mouse CD4+ T cell transcriptomes.
    1. Zhu J
    2. Jankovic D
    3. Oler AJ
    4. Wei G
    5. Sharma S
    6. Hu G
    7. Guo L
    8. Yagi R
    9. Yamane H
    10. Punkosdy G
    11. Feigenbaum L
    12. Zhao K
    13. Paul WE
    (2012) NCBI Gene Expression Omnibus
    ID GSE38808. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses.

References

Decision letter

  1. Stipan Jonjic
    Reviewing Editor; University of Rijeka, Croatia
  2. Satyajit Rath
    Senior Editor; Indian Institute of Science Education and Research (IISER), India

Our editorial process produces two outputs: i) public reviews designed to be posted alongside the preprint for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed their reviews with one another, and since they raise distinct crucial questions, it is requested that you respond, either with additional evidence and/or with clarifications, to the individual reviews below.

Reviewer #1 (Recommendations for the authors):

Although the results of the present study are interesting and potentially relevant, some questions remained unanswered.

1. Although it is well known that CD4 T cells, rather than CD8 cells, are pivotal in controlling MCMV in the SG, the use of Cd4cre mice might have also affected the functionality of CD8 cells. This question should be experimentally addressed.

2. It remains unclear how Arg-1 expression was regulated and whether this effect is specific/limited to the salivary gland. What is the experimental evidence that frequent antigen exposure triggers Arg1 expression?

3. Does Arg1 causes MCMV persistence, or does the virus persistence in the SG trigger the formation of IL-10-producing Arg1 positive CD4 T cells? Since MCMV can persist for months in the salivary glands, even in immunocompetent mice, the dynamics of IL-10-producing CD4 T cells during and after the resolution of persistent infection should be investigated.

4. It is well established that a single passage of tissue-culture-derived MCMV is sufficient to result in a highly virulent MCMV. Therefore, comparing the virulence of salivary gland-derived MCMV from Arg1 positive and Arg1 negative mice would be informative.

Reviewer #2 (Recommendations for the authors):

The novelty of the findings are limited by a recent paper (JCI Insight. 2019 Dec 19; 4(24): e129756) that shows that Arginase-2 in FOXP3+Tregs contributes to suppression. This study has to be quoted and discussed.

Il-10-T-cells in Figure 1 and 2 might contain bystander cells that could even be entirely responsible for the differences in gene expression and clonal expansions. This needs to be ruled out. IFN-g producing Il-10- cells would have been much more convincing. A list of differentially expressed genes is missing, how were the shown genes selected, by p-value, fold expression or arbitrarily?

Figure 3: Inducible CD4 Cre mice would have been much more convincing to rule out a contribution of CD8+T-cells (it is stated in the Discussion that CD8+T-cells do not express arginase, but this data needs to be shown). It must also be controlled if arginase is expressed in IL-10- cells, otherwise the Figure title is simply an overstatement. CD4-Cre mice without the floxed alleles need to be analysed as controls.

Figure 4//5: Based on the literature a similar role could be expected for the related T-box transcription factor Eomesodermin, the choice of T-bet seems a bit arbitrary. T-bet ko cells fail to differentiate to effector cells, the molecular mechanism of arginase-1 induction remains therefore unclear, as also admitted by the authors.

Reviewer #3 (Recommendations for the authors):

Figure 1:

To which extent Thy1.1 expression correlates with IL-10 protein staining in the SG of MCMV-infected mice? This should be provided in the supplement. Are all of these, or the majority of these cells, antigen-specific, i.e. what would be the correlation with for example available M25 tetramer staining or peptide pool restimulation?

It remains unclear to which extent the phenotype of in vivo generated IL-10+CD4+T cells overlaps with conventional in vivo generated Th1 cells (maybe even ones of acutely MCMV-infected mice), cytotoxic Th1 cells (for example lung cytotoxic Th1 cells) and Tr1-like cells (either generated in vitro with IL-27 and TGFb or isolated from an in vivo setting). Which gene families constitute 1646 DEG in Figure 1E.

The authors could also co-stain IFNγ and GzmB with Thy1.1 after polyclonal or even antigen-stimulation in vitro.

Some genes associated with the induction of IFN-g, including Il18r1 and il18rap, were downregulated in Thy1.1+ CD4+ T cells, however IFNγ does not seem to be differentially regulated, or? While Thy1.1+ cells express a module of inhibitory genes, their expression of Tcf1/Tcf7 seems to be downregulated? Is any difference in the expression of Tox observed?

Figure 2:

The authors show that the Thy1.1+ pool shows a narrower and more convergent repertoire, which could be an indication of a clonally expanded population. VDJtools, which the authors use, offers a more comprehensive diversity estimation with PlotQuantileStats. This would enable the authors to visualize the repertoire clonality of Thy1.1+ vs Thy1.1- pools.

For better understanding, is the clonality analysis performed on a sample derived of several pooled mice? Have the authors had the opportunity to assess the degree of clone sharing between e.g., splenic and salivary gland cells?

Figure 3:

The authors demonstrate higher transcript levels and open chromatin structures of Arg1 in Thy1.1+ cells. They should provide a co-staining of Arg-1 and Thy1.1 on a protein level.

Although CD4 T cells are critical in controlling MCMV in the SG, Cd4cre mice target also CD8 and NKT cells can the authors confirm there is no Arginase-1 expression in these cells as well that could contribute to MCMV control in SG? This could potentially be solved by adoptive transfer of WT vs. Arg1-/- CD4 T cells. Otherwise, conclusion of this figure should be downplayed as it is not clear that Arg1 expression by CD4+ t cells selectively inhibit accumulation of virus-specific CD4+ and CD8+ T cells.

Is there any impact on the IL-10 expression by CD4+ T cells observed in the SG of CD4Cre Arg1flox mice infected with MCMV?

NK cells are known to contribute to the viral control in SG and TRAIL+ NK cells capable of killing activated CD4+ T cells accumulate in the SG during CMV infection (Schuster et al. 2011). Do the authors observe any differences in the expression of DR5 in relation to Thy1.1?

Are there any functional and phenotypical advantages in the CD4+ T cell compartment of uninfected mice?

The proliferation effect observed in CD4CreArg1flox mice – can it be reversed by Arginase-1 supplementation?

Figure 4:

In figure 3A, are the CD4 T cells pre-gated on CD44? One would assume that the majority of CD4+ T cells in the SG during CMV infection would be T-bet+, i.e., of Th1 phenotype. Can this be attributed to the technical issue of T-bet staining? Also does the FMO/Ab staining come from the same mouse as the % of Thy1.1 cells seem to increase from upper (11.9%) to lower (19.43%) plot?

Figure 5:

In this figure the authors demonstrate that IFNγ-expressing cells are increased with T-bet deficiency and as a result the virus is cleared better. What is the correlation between IFN-g and Arg-1 expression? Are the virus specific IFNγ-producing cells in T-bet-deficient mice also of CD44loPD-1loCD62Lhi phenotype? The title of the figure says that IL-10-producing CD4+ T cells develop in a T-bet-dependent manner, however the authors do not probe for IL-10 expression here.

What formal proof demonstrates that repetitive antigen exposure results in Arginase-1 upregulation? This could potentially be mimicked in vitro (Saraiva et al., 2009).

In Figure 5H, significance in viral clearance seems to be driven by a number of plaques observed in a sample of one mouse. Even like that, the difference does not reach even half a log a difference. I suggest increasing n to strengthen this result. In contrast to Cd4Cre Tbet-flox mice which seem to compensate for the lack of T-bet by day 28 there is no protective effect, viral control is still observed in Cd4Cre Arg1flox (this paper) and CD4Cre IL10-flox (author´s previous publication Clement et al., 2016). How do the authors comment on this?

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1" for further consideration by eLife. Your revised article has been evaluated by 2 reviewers, Satyajit Rath (Senior Editor) and a Reviewing Editor.

Although the conclusion was that the manuscript has been improved, there are some remaining issues that need to be addressed, as outlined below. Please note that we do not expect you to add new data, but to discuss your findings in the light of suggestions which can be found below.

Reviewer #2 (Recommendations for the authors):

In the revision, the authors have performed all requested experiments.

I do however not think that the interpretation of their data is acceptable in its current form, because they ignore a large body of published evidence on IL-10 producing T-cells that is highly relevant to their study. There is already a lot of confusion in the field, and ignoring seminal work performed by others does not contribute to reaching a general consensus on the molecular identity of these cells.

The authors show in supplementary Figure 5 that IL-10 producing regulatory T-cells express high levels of Eomesodermin, a rather surprising finding for CD4+T-cells, but comment on this data only briefly on p11: "No such difference in expression frequency were observed for the related transcription factor Eomesodermin (Eomes)". This is really a misleading statement since the authors do show that the MFI of Eomes is higher in IL-10 producing T-cells. However, no statistical analysis is provided, and a control with CD4+T-cells in the absence of CMV infection (presumably Eomes-negative) is also missing. In any case, the large majority of IL-10+ T-cells express high levels of Eomesodermin, while the staining of T-bet suggests that T-bet expression may be actually lower (of course this may be due to technical issues). Thus, the choice to focus on T-bet rather than on Eomes is in my opinion an arbitrary one. I understand that it would take too much work to perform all relevant experiments both with T-bet and Eomes-deficient T-cells in a revision, but ignoring all the published evidence on Eomesodermin-expressing, IL-10 producing CD4+T-cells is simply unacceptable. The authors state moreover in the Introduction that IL-10 producing T-cells in their system "are phenotypically different from type 1 regulatory T-cells (Clement 2016)" In their cited work I could not find a detailed phenotypic characterization, so it is unclear to me how the authors came to this conclusion. Moreover, in the revised article, they document in contrast that the IL-10 producing "inhibitory" T-cells they study do express all markers that are well-known to be associated with Tr1-cells, namely LAG3, PD1 and other checkpoint receptors, CCR5, GzmK etc etc.(Brockmann, Soukou et al. 2018, Roessner, Llao Cid et al. 2021, Thelen, Schipperges et al. 2023) Thus, the relationship of the IL-10 producing "inhibitory" T-cells to Tr1-cells, in particular those that express Eomes, needs to be discussed in detail and the relevant articles have to be cited. Notably, also Eomes-expressing Tr1-cells are T-bet dependent (Zhang, Lee et al. 2017) and clonally expanded (Bonnal, Rossetti et al. 2021).

Bonnal, R. J. P., G. Rossetti, E. Lugli, M, et. al. (2021). "Clonally expanded EOMES(+) Tr1-like cells in primary and metastatic tumors are associated with disease progression." Nat Immunol 22(6): 735-745.

Brockmann, L., S. Soukou, B. Steglich, et. al. (2018). "Molecular and functional heterogeneity of IL-10-producing CD4(+) T cells." Nat Commun 9(1): 5457.

Roessner, P. M., L. Llao Cid, E. Lupar, T, et. al. (2021). "EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia." Leukemia 35(8): 2311-2324.

Thelen, B., V. Schipperges, P. Knorlein, J. F, et. al. (2023). "Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4(+) T cells." Front Immunol 14: 1058267.

Zhang, P., J. S. Lee, K. H. Gartlan, I. S, et. al. (2017). "Eomesodermin promotes the development of type 1 regulatory T (TR1) cells." Sci Immunol 2(10).

https://doi.org/10.7554/eLife.79165.sa1

Author response

Reviewer #1 (Recommendations for the authors):

Although the results of the present study are interesting and potentially relevant, some questions remained unanswered.

1. Although it is well known that CD4 T cells, rather than CD8 cells, are pivotal in controlling MCMV in the SG, the use of Cd4cre mice might have also affected the functionality of CD8 cells. This question should be experimentally addressed.

We now show that CD4 depletion but not CD8 depletion impacts Arg1 protein concentrations in salivary gland homogenates during chronic infection with MCMV (Figure 3—figure supplement 3B).

2. It remains unclear how Arg-1 expression was regulated and whether this effect is specific/limited to the salivary gland. What is the experimental evidence that frequent antigen exposure triggers Arg1 expression?

To address this issue, we stimulated OVA-specific transgenic CD4+ T cells with high-dose or low-dose antigen ± IL-12, which has been shown previously to induce the expression of IL-10 among Th1 cells, as highlighted by Reviewer 3. Only the combination of high-dose antigen ± IL-12 induced Arg1+ IL-10-producing cells (Figure 3D) and the secretion of substantial amounts of Arg1 (Figure 3E). These data suggest that high-dose antigen exposure acts similarly during chronic infection with MCMV. See also pages 9, 10, 15, and 23.

3. Does Arg1 causes MCMV persistence, or does the virus persistence in the SG trigger the formation of IL-10-producing Arg1 positive CD4 T cells? Since MCMV can persist for months in the salivary glands, even in immunocompetent mice, the dynamics of IL-10-producing CD4 T cells during and after the resolution of persistent infection should be investigated.

We showed previously that virus-specific IL10-producing CD4+ T cells developed in the salivary glands, peaked on day 14 p.i., and then contracted after infection with MCMV, suggesting a determinative role for initially high levels of viral replication (Figure 1B in Clement et al., PLoS Pathog, 2016). These findings are supported by our new data showing that Arg1+ IL-10-producing CD4+ T cells develop in vitro in response to high-dose antigen stimulation in the presence of IL-12 (Figure 3E).

4. It is well established that a single passage of tissue-culture-derived MCMV is sufficient to result in a highly virulent MCMV. Therefore, comparing the virulence of salivary gland-derived MCMV from Arg1 positive and Arg1 negative mice would be informative.

We attempted this experiment with the aim of generating virus from CD4cre−Arg1flox+/+ and CD4cre+Arg1flox+/+ mice. However, we obtained very low titres (<3 × 103 PFU) from pools of 3–5 mice, which were insufficient for challenge experiments to assess in vivo pathogenicity. We believe that >30–50 mice per group would therefore be required to address this possibility, which we feel is perhaps not justified here given that such experiments would not alter the main conclusions of our study. We have nonetheless mentioned this interesting possibility on page 15.

Reviewer #2 (Recommendations for the authors):

The novelty of the findings are limited by a recent paper (JCI Insight. 2019 Dec 19; 4(24): e129756) that shows that Arginase-2 in FOXP3+Tregs contributes to suppression. This study has to be quoted and discussed.

We thank the reviewer for drawing our attention to this relevant study, which is now highlighted in context and cited on page 14.

Il-10-T-cells in Figure 1 and 2 might contain bystander cells that could even be entirely responsible for the differences in gene expression and clonal expansions. This needs to be ruled out. IFN-g producing Il-10- cells would have been much more convincing.

To address this possibility, we first identified IFN-γ+ CD4+ T cells and then compared the expression of two proteins that were preferentially upregulated among Thy1.1+ CD4+ T cells, namely LAG-3 and PD-1. These proteins were significantly upregulated among IFN-γ+ Thy1.1+ CD4+ T cells versus IFN-γ+ Thy1.1 CD4+ T cells, arguing against a major role for bystander activation (Figure 1—figure supplement 1E).

A list of differentially expressed genes is missing, how were the shown genes selected, by p-value, fold expression or arbitrarily?

All genes shown are significant at p < 0.05 and were selected for heatmap representation based on relevant pathways identified using gene ontology functions as tabulated and now clarified in the legend for Figure 1D. Our full dataset is available at https://doi.org/10.5281/zenodo.7243956.

Figure 3: Inducible CD4 Cre mice would have been much more convincing to rule out a contribution of CD8+T-cells (it is stated in the Discussion that CD8+T-cells do not express arginase, but this data needs to be shown).

We did not refer to Arg1 expression by CD8+ T cells in the original Discussion. However, we now show that CD8+ T cells do indeed express Arg1 (Figure 3—figure supplement 3A), but that only CD4 depletion impacts Arg1 protein concentrations in salivary gland homogenates during chronic infection with MCMV (Figure 3—figure supplement 3B). We also show that CD4+ T cells secrete Arg1 in vitro (Figure 3D). These data suggest that CD4+ T cells rather than CD8+ T cells are the primary source of Arg1 during the chronic phase of infection with MCMV. We discuss these data on page 13.

It must also be controlled if arginase is expressed in IL-10- cells, otherwise the Figure title is simply an overstatement.

The intracellular detection of Arg1 via flow cytometry proved to be suboptimal in our analyses of C57BL/6 mice (discussed on page 13). However, we now show that only conditions that induce IL-10-producing CD4+ T cells induce the secretion of substantial amounts of Arg1 (Figure 3E). These data are consistent with the conclusion that the upregulation of Arg1 is a hallmark of inhibitory CD4+ T cells, which are also likely the predominant source of secreted Arg1 within the CD4+ T cell compartment. We discuss these data on pages 9, 10, and 15. We have also amended the title of the relevant legend for clarity (now Figure 4).

CD4-Cre mice without the floxed alleles need to be analysed as controls.

We now show that viral chronicity is not influenced by the floxed alleles in a comparison of CD4cre+Argflox+ mice and unfloxed CD4cre+ mice (Figure 4—figure supplement 4A).

Figure 4//5: Based on the literature a similar role could be expected for the related T-box transcription factor Eomesodermin, the choice of T-bet seems a bit arbitrary.

In contrast to T-bet, we did not observe enriched expression of Eomes protein (Figure 5—figure supplement 5 A, B), as now highlighted on page 11.

T-bet ko cells fail to differentiate to effector cells, the molecular mechanism of arginase-1 induction remains therefore unclear, as also admitted by the authors.

We now include new data showing that high-dose antigen drives the development of Arg1+ CD4+ T cells and Arg1+ IL-10-producing CD4+ T cells (Figure 3D, E). The putative molecular mechanisms are now discussed more fully on page 16.

Reviewer #3 (Recommendations for the authors):

Figure 1:

To which extent Thy1.1 expression correlates with IL-10 protein staining in the SG of MCMV-infected mice? This should be provided in the supplement.

We now show these data in Figure 1—figure supplement 1B.

Are all of these, or the majority of these cells, antigen-specific, i.e. what would be the correlation with for example available M25 tetramer staining or peptide pool restimulation?

This is an interesting point. Frustratingly, we do not believe that using M25 tetramers would help answer this question definitely in our non-TCR transgenic mouse system, given the breadth of the MCMV-specific CD4+ T cell response (e.g., Arens et al., J Immunol, 2008; Walton et al., J Immunol, 2008), which extends to CD4+ T cells in the salivary glands that produce IL-10 (Clement et al., PLoS Pathog, 2016). Moreover, it is clear from in vitro assays using PMA and ionomycin to stimulate CD4+ T cells isolated from the salivary glands that IL-10 is inefficiently detected via flow cytometry compared with Thy1.1 (Figure 1—figure supplement 1B), which makes even pooled peptide restimulation experiments difficult to perform with any degree of sensitivity. However, approximately 25% of Thy1.1+ CD4+ T cells coexpressed IFNγ in response to polyclonal stimulation (Figure 1—figure supplement 1E), suggesting they were derived from virus-specific Th1 cells, and even this figure is likely an underestimate of virus-specific CD4+ T cell frequencies based on data from CD4 transgenic mice (Jeitziner et al., Eur J Immunol, 2013). It therefore seems likely that most Thy1.1+ CD4+ T cells are indeed specific for MCMV (now discussed on page 6).

It remains unclear to which extent the phenotype of in vivo generated IL-10+CD4+T cells overlaps with conventional in vivo generated Th1 cells (maybe even ones of acutely MCMV-infected mice), cytotoxic Th1 cells (for example lung cytotoxic Th1 cells) and Tr1-like cells (either generated in vitro with IL-27 and TGFb or isolated from an in vivo setting).

We have shown previously that IL-10-producing CD4+ T cells are not IL-27-inducible and are phenotypically distinct from Tr1 cells (Clement et al., PLoS Pathogens, 2016). These cells also lack granzyme B and do not express genes that classically demarcate cytotoxic CD4+ T cells, such as Crtam and Klrc1, which encode NKG2A and NKG2D, respectively. Moreover, approximately 25% of Thy1.1+ CD4+ T cells expressed IFNγ in response to polyclonal stimulation (Figure 1—figure supplement 1E), and associated genes (e.g., IL-18R) were downregulated among Thy1.1+ CD4+ T cells (Figure 1D). We also now show that IFNγ+ Thy1.1+ CD4+ T cells upregulate inhibitory receptors compared with IFNγ+ Thy1.1 CD4+ T cells (Figure 1—figure supplement 1E). These data are consistent with the conclusion that IL-10-producing CD4+ T cells derive from Th1 cells generated in vivo but exhibit increased expression of secreted and membrane-bound inhibitory molecules and reduced production of IFNγ in response to cognate antigen stimulation. These observations are discussed on pages 4, 6, and 7.

Which gene families constitute 1646 DEG in Figure 1E.

Shared pathways are now available at https://doi.org/10.5281/zenodo.7447477. See also page 6.

The authors could also co-stain IFNγ and GzmB with Thy1.1 after polyclonal or even antigen-stimulation in vitro.

We failed to detect granzyme B expression via flow cytometry (Author response image 1), suggesting a disconnect between granzyme B message (RNAseq) and translation. This is now mentioned on page 6.

Author response image 1
Granzyme B protein expression by salivary gland CD44 is not detectable by flow cytometry.

Granzyme B and Thy1.1 expression by salivary gland CD4 T cells was assessed by flow cytometry 14 days after MCMV infection of 10-Bit mice.

Some genes associated with the induction of IFN-g, including Il18r1 and il18rap, were downregulated in Thy1.1+ CD4+ T cells, however IFNγ does not seem to be differentially regulated, or? While Thy1.1+ cells express a module of inhibitory genes, their expression of Tcf1/Tcf7 seems to be downregulated?

Our data represent a snapshot of gene expression. It is therefore likely that some disconnect exists between certain patterns of gene and protein expression.

Is any difference in the expression of Tox observed?

Tox1 is actually downregulated in Thy1.1+ cells (Figure 1D). We now highlight this finding on page 7.

Figure 2:

The authors show that the Thy1.1+ pool shows a narrower and more convergent repertoire, which could be an indication of a clonally expanded population. VDJtools, which the authors use, offers a more comprehensive diversity estimation with PlotQuantileStats. This would enable the authors to visualize the repertoire clonality of Thy1.1+ vs Thy1.1- pools.

We have now included an analysis using PlotQuantileStats (Figure 2—figure supplement 2A).

For better understanding, is the clonality analysis performed on a sample derived of several pooled mice?

Clonality and other metrics were assessed using a minimum of four mice per group pooled across three independent experiments (m1, m2, and m3) as clarified in the legend for Figure 2.

Have the authors had the opportunity to assess the degree of clone sharing between e.g., splenic and salivary gland cells?

We have not performed this experiment. The kinetics of IL-10-producing CD4+ T cell responses at these sites are very different, and by day 14 p.i., there are very few IL-10-producing CD4+ T cells in the spleen (Clement et al., PLoS Pathog, 2016). A direct comparison of these compartments at a single time point would therefore be difficult to undertake and possibly even more difficult to interpret meaningfully.

Figure 3:

The authors demonstrate higher transcript levels and open chromatin structures of Arg1 in Thy1.1+ cells. They should provide a co-staining of Arg-1 and Thy1.1 on a protein level.

The intracellular detection of Arg1 via flow cytometry proved to be suboptimal in our analyses of C57BL/6 mice (discussed on page 13), but we have now included new data suggesting that Arg1 expression is indeed enriched among Thy1.1+ CD4+ T cells in the salivary glands (Figure 3C). We also show that only conditions that induce IL-10-producing CD4+ T cells induce the secretion of substantial amounts of Arg1 (Figure 3E). These data are consistent with the conclusion that the upregulation of Arg1 is a hallmark of inhibitory CD4+ T cells, which are also likely the predominant source of secreted Arg1 within the CD4+ T cell compartment. We discuss these data on pages 9, 10, and 15.

Although CD4 T cells are critical in controlling MCMV in the SG, Cd4cre mice target also CD8 and NKT cells can the authors confirm there is no Arginase-1 expression in these cells as well that could contribute to MCMV control in SG? This could potentially be solved by adoptive transfer of WT vs. Arg1-/- CD4 T cells. Otherwise, conclusion of this figure should be downplayed as it is not clear that Arg1 expression by CD4+ t cells selectively inhibit accumulation of virus-specific CD4+ and CD8+ T cells.

We now show that CD4 depletion but not CD8 depletion impacts Arg1 protein concentrations in salivary gland homogenates during chronic infection with MCMV (Figure 3—figure supplement 3B).

Is there any impact on the IL-10 expression by CD4+ T cells observed in the SG of CD4Cre Arg1flox mice infected with MCMV?

We now show that T cell-specific knockdown of Arg1 does not significantly impact virus-specific IL-10-producing CD4+ T cell responses, unlike virus-specific IFNγ+ CD4+ T cell responses (Figure 4D). These data suggest that Arg1 does not drive the development of these cells, as discussed on page 10.

NK cells are known to contribute to the viral control in SG and TRAIL+ NK cells capable of killing activated CD4+ T cells accumulate in the SG during CMV infection (Schuster et al. 2011). Do the authors observe any differences in the expression of DR5 in relation to Thy1.1?

We detected no differential expression of Trailr in Thy1.1+ CD4+ T cells versus Thy1.1 CD4+ T cells, implying that the transient nature of these cells is likely not due to killing via TRAIL (https://doi.org/10.5281/zenodo.7243956). See also page 7.

Are there any functional and phenotypical advantages in the CD4+ T cell compartment of uninfected mice?

We now show that T cell-specific depletion of Arg1 has no obvious impact on the function or phenotype of CD4+ T cells in naive mice (Figure 3—figure supplement 3C, D).

The proliferation effect observed in CD4CreArg1flox mice – can it be reversed by Arginase-1 supplementation?

We do not believe that injecting Arg1 protein into mice will likely have a biologically meaningful impact on T cell responses in the salivary glands during chronic infection with MCMV. However, we have now inserted reference to human data demonstrating that Arg1 suppresses T cell proliferation (page 13).

Figure 4:

In figure 3A, are the CD4 T cells pre-gated on CD44? One would assume that the majority of CD4+ T cells in the SG during CMV infection would be T-bet+, i.e., of Th1 phenotype. Can this be attributed to the technical issue of T-bet staining? Also does the FMO/Ab staining come from the same mouse as the % of Thy1.1 cells seem to increase from upper (11.9%) to lower (19.43%) plot?

We thank the reviewer for highlighting this issue. The representative plots were from different mice. The reviewer is probably correct that all activated CD4+ T cells will be T-bet+ in this model system. However, ex vivo T-bet staining is never particularly bright in our experience, particularly among T cells isolated from the salivary glands, and accordingly, we now show these data as histogram overlays with FMOs (Figure 5A).

Figure 5:

In this figure the authors demonstrate that IFNγ-expressing cells are increased with T-bet deficiency and as a result the virus is cleared better. What is the correlation between IFN-g and Arg-1 expression?

The transient impact of T-bet depletion on viral replication likely represents a combination of factors, and accordingly, we do not necessarily expect to see a clear association between Arg1 and the expression of IFNγ. We have nonetheless shown that T-bet deficiency impinges on the development of virus-specific IL-10-producing CD4+ T cells (Figure 6A).

Are the virus specific IFNγ-producing cells in T-bet-deficient mice also of CD44loPD-1loCD62Lhi phenotype?

Our attempts to address this question using peptide-specific CD4+ T cells isolated from the salivary glands were inconclusive due to low overall cell numbers and low frequencies of virus-specific CD4+ T cells, as highlighted elsewhere. We therefore reverted to polyclonal stimulation, which unfortunately led to the downregulation of CD62L (see Author response image 2). We would be happy to attempt further peptide stimulations with much larger group numbers/pooled samples if the reviewer feels these data are essential to support the conclusions of our study. However, we would prefer not to conduct these experiments if the reviewer concurs, because the required number of mice would be considerable and therefore ethically questionable.

Author response image 2

The title of the figure says that IL-10-producing CD4+ T cells develop in a T-bet-dependent manner, however the authors do not probe for IL-10 expression here.

We now include an analysis of IL-10-producing virus-specific CD4+ T cells, demonstrating reduced accumulation of these cells following the depletion of T-bet (Figure 6A).

What formal proof demonstrates that repetitive antigen exposure results in Arginase-1 upregulation? This could potentially be mimicked in vitro (Saraiva et al., 2009).

We thank the reviewer for this insightful suggestion. To address this issue, we stimulated OVA-specific transgenic CD4+ T cells with high-dose or low-dose antigen ± IL-12, which has been shown previously to induce the expression of IL-10 among Th1 cells (Saraiva et al., Immunity, 2009). Only the combination of high-dose antigen ± IL-12 induced Arg1+ IL-10-producing cells (Figure 3D) and the secretion of substantial amounts of Arg1 (Figure 3E). These data suggest that high-dose antigen exposure acts similarly during chronic infection with MCMV. See also pages 9, 10, 15, and 23.

In Figure 5H, significance in viral clearance seems to be driven by a number of plaques observed in a sample of one mouse. Even like that, the difference does not reach even half a log a difference. I suggest increasing n to strengthen this result.

We have increased the numbers as requested by the reviewer, focusing the data on day 14 p.i. (now Figure 6I). The plaque assay data from the later time point are now shown in Figure 5—figure supplement 5D.

In contrast to Cd4Cre Tbet-flox mice which seem to compensate for the lack of T-bet by day 28 there is no protective effect, viral control is still observed in Cd4Cre Arg1flox (this paper) and CD4Cre IL10-flox (author´s previous publication Clement et al., 2016). How do the authors comment on this?

We comment on this issue on page 12.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Reviewer #2 (Recommendations for the authors):

In the revision, the authors have performed all requested experiments.

I do however not think that the interpretation of their data is acceptable in its current form, because they ignore a large body of published evidence on IL-10 producing T-cells that is highly relevant to their study. There is already a lot of confusion in the field, and ignoring seminal work performed by others does not contribute to reaching a general consensus on the molecular identity of these cells.

The authors show in supplementary Figure 5 that IL-10 producing regulatory T-cells express high levels of Eomesodermin, a rather surprising finding for CD4+T-cells, but comment on this data only briefly on p11: "No such difference in expression frequency were observed for the related transcription factor Eomesodermin (Eomes)". This is really a misleading statement since the authors do show that the MFI of Eomes is higher in IL-10 producing T-cells. However, no statistical analysis is provided, and a control with CD4+T-cells in the absence of CMV infection (presumably Eomes-negative) is also missing. In any case, the large majority of IL-10+ T-cells express high levels of Eomesodermin, while the staining of T-bet suggests that T-bet expression may be actually lower (of course this may be due to technical issues). Thus, the choice to focus on T-bet rather than on Eomes is in my opinion an arbitrary one. I understand that it would take too much work to perform all relevant experiments both with T-bet and Eomes-deficient T-cells in a revision, but ignoring all the published evidence on Eomesodermin-expressing, IL-10 producing CD4+T-cells is simply unacceptable.

We have now expanded our introduction of this data, quoting on page 11 that we do not see a significant difference in Eomes protein between Thy1.1+ and Thy1.1- CD4+ T cells (data shown in Author response image 3 and quoted on page 11). We discuss the potential relevance of EOMES in the development of SG CD4+IL10+ T cells on page 16.

Author response image 3
Eomes expression by Thy1.

1+ and Thy1.1- CD4+ T cells 14 days post-MCMV infection.

The authors state moreover in the Introduction that IL-10 producing T-cells in their system "are phenotypically different from type 1 regulatory T-cells (Clement 2016)" In their cited work I could not find a detailed phenotypic characterization, so it is unclear to me how the authors came to this conclusion.

We have revised this statement for improved clarity (page 4).

Moreover, in the revised article, they document in contrast that the IL-10 producing "inhibitory" T-cells they study do express all markers that are well-known to be associated with Tr1-cells, namely LAG3, PD1 and other checkpoint receptors, CCR5, GzmK etc etc.(Brockmann, Soukou et al. 2018, Roessner, Llao Cid et al. 2021, Thelen, Schipperges et al. 2023) Thus, the relationship of the IL-10 producing "inhibitory" T-cells to Tr1-cells, in particular those that express Eomes, needs to be discussed in detail and the relevant articles have to be cited. Notably, also Eomes-expressing Tr1-cells are T-bet dependent (Zhang, Lee et al. 2017) and clonally expanded (Bonnal, Rossetti et al. 2021).

We thank the reviewer and have inserted a paragraph on pages 15-16 to address these important studies.

https://doi.org/10.7554/eLife.79165.sa2

Article and author information

Author details

  1. Mathew Clement

    1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    clementm@cardiff.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9280-5281
  2. Kristin Ladell

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
  3. Kelly L Miners

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation
    Competing interests
    No competing interests declared
  4. Morgan Marsden

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
  5. Lucy Chapman

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation
    Competing interests
    No competing interests declared
  6. Anna Cardus Figueras

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
  7. Jake Scott

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Data curation
    Competing interests
    No competing interests declared
  8. Robert Andrews

    1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Resources, Formal analysis
    Competing interests
    No competing interests declared
  9. Simon Clare

    Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom
    Contribution
    Data curation
    Competing interests
    No competing interests declared
  10. Valeriia V Kriukova

    1. Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    2. Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
    3. Institute of Clinical Molecular Biology, Christian-Albrecht-University of Kiel, Kiel, Germany
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
  11. Ksenia R Lupyr

    1. Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    2. Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
    3. Institute of Translational Medicine, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
  12. Olga V Britanova

    1. Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
    2. Institute of Clinical Molecular Biology, Christian-Albrecht-University of Kiel, Kiel, Germany
    3. Institute of Translational Medicine, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Contribution
    Data curation, Formal analysis, Funding acquisition, Writing – review and editing
    Competing interests
    No competing interests declared
  13. David R Withers

    Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
    Contribution
    Resources, Formal analysis, Funding acquisition
    Competing interests
    No competing interests declared
  14. Simon A Jones

    1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Resources, Formal analysis
    Competing interests
    No competing interests declared
  15. Dmitriy M Chudakov

    1. Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    2. Genomics of Adaptive Immunity Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
    3. Institute of Translational Medicine, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Moscow, Russian Federation
    4. Abu Dhabi Stem Cell Center, Al Muntazah, United Arab Emirates
    Contribution
    Data curation, Formal analysis, Funding acquisition, Writing – review and editing
    Competing interests
    No competing interests declared
  16. David A Price

    1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Resources, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9416-2737
  17. Ian R Humphreys

    1. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
    2. Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Contribution
    Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9512-5337

Funding

Wellcome Trust (207503/Z/17/Z)

  • Ian R Humphreys

Wellcome Trust (100326/Z/12/Z)

  • David A Price

Wellcome Trust (110199/Z/15/Z)

  • David R Withers

Deutsche Forschungsgemeinschaft (Cluster of Excellence "Precision Medicine in Chronic Inflammation")

  • Valeriia V Kriukova

Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1789)

  • Dmitriy M Chudakov

Wellcome Trust (209213/Z/17/Z)

  • Ian R Humphreys

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Acknowledgements

We thank Steven Reiner (Columbia University, New York, USA) for providing Tbx21flox/flox mice, Joerg Fehling (Ulm University, Germany) for providing Rosa26flSTOPtdRFP mice, and Sarah Dimeloe (University of Birmingham, UK) for providing Cd4Cre/+ mice. Biotinylated monomers were obtained from the NIH Tetramer Core Facility. MC was supported by a Systems Immunity Research Institute Fellowship (Cardiff University). VVK received infrastructure support from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI). OVB, DMC, and DAP were supported by a Ministry of Science and Higher Education of the Russian Federation Subsidy Grant (075-15-2019-1789). DRW was supported by a Wellcome Trust Senior Research Fellowship (110199/Z/15/Z). DAP was supported by a Wellcome Trust Senior Investigator Award (100326/Z/12/Z). IRH was supported by a Medical Research Council Confidence in Concept Award, a Wellcome Trust Collaborator Award (209213/Z/17/Z), and a Wellcome Trust Senior Research Fellowship (207503/Z/17/Z).

Ethics

All mouse experiments were approved by the Biological Services Facility (Cardiff University) and performed under UK Home Office Project License P7867DADD.

Senior Editor

  1. Satyajit Rath, Indian Institute of Science Education and Research (IISER), India

Reviewing Editor

  1. Stipan Jonjic, University of Rijeka, Croatia

Version history

  1. Preprint posted: January 27, 2022 (view preprint)
  2. Received: April 1, 2022
  3. Accepted: May 11, 2023
  4. Version of Record published: July 13, 2023 (version 1)

Copyright

© 2023, Clement et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 333
    Page views
  • 63
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mathew Clement
  2. Kristin Ladell
  3. Kelly L Miners
  4. Morgan Marsden
  5. Lucy Chapman
  6. Anna Cardus Figueras
  7. Jake Scott
  8. Robert Andrews
  9. Simon Clare
  10. Valeriia V Kriukova
  11. Ksenia R Lupyr
  12. Olga V Britanova
  13. David R Withers
  14. Simon A Jones
  15. Dmitriy M Chudakov
  16. David A Price
  17. Ian R Humphreys
(2023)
Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1
eLife 12:e79165.
https://doi.org/10.7554/eLife.79165

Further reading

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Roshni Roy, Pei-Lun Kuo ... Luigi Ferrucci
    Research Article Updated

    Age-associated DNA methylation in blood cells convey information on health status. However, the mechanisms that drive these changes in circulating cells and their relationships to gene regulation are unknown. We identified age-associated DNA methylation sites in six purified blood-borne immune cell types (naive B, naive CD4+ and CD8+ T cells, granulocytes, monocytes, and NK cells) collected from healthy individuals interspersed over a wide age range. Of the thousands of age-associated sites, only 350 sites were differentially methylated in the same direction in all cell types and validated in an independent longitudinal cohort. Genes close to age-associated hypomethylated sites were enriched for collagen biosynthesis and complement cascade pathways, while genes close to hypermethylated sites mapped to neuronal pathways. In silico analyses showed that in most cell types, the age-associated hypo- and hypermethylated sites were enriched for ARNT (HIF1β) and REST transcription factor (TF) motifs, respectively, which are both master regulators of hypoxia response. To conclude, despite spatial heterogeneity, there is a commonality in the putative regulatory role with respect to TF motifs and histone modifications at and around these sites. These features suggest that DNA methylation changes in healthy aging may be adaptive responses to fluctuations of oxygen availability.

    1. Immunology and Inflammation
    2. Neuroscience
    René Lemcke, Christine Egebjerg ... Birgitte R Kornum
    Research Article

    Infection with Influenza A virus (IAV) causes the well-known symptoms of the flu, including fever, loss of appetite, and excessive sleepiness. These responses, mediated by the brain, will normally disappear once the virus is cleared from the system, but a severe respiratory virus infection may cause long-lasting neurological disturbances. These include encephalitis lethargica and narcolepsy. The mechanisms behind such long lasting changes are unknown. The hypothalamus is a central regulator of the homeostatic response during a viral challenge. To gain insight into the neuronal and non-neuronal molecular changes during an IAV infection, we intranasally infected mice with an H1N1 virus and extracted the brain at different time points. Using single-nucleus RNA sequencing (snRNA-seq) of the hypothalamus, we identify transcriptional effects in all identified cell populations. The snRNA-seq data showed the most pronounced transcriptional response at 3 days past infection, with a strong downregulation of genes across all cell types. General immune processes were mainly impacted in microglia, the brain resident immune cells, where we found increased numbers of cells expressing pro-inflammatory gene networks. In addition, we found that most neuronal cell populations downregulated genes contributing to the energy homeostasis in mitochondria and protein translation in the cytosol, indicating potential reduced cellular and neuronal activity. This might be a preventive mechanism in neuronal cells to avoid intracellular viral replication and attack by phagocytosing cells. The change of microglia gene activity suggest that this is complemented by a shift in microglia activity to provide increased surveillance of their surroundings.